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Timely diagnosis of acute coronary syndrome (ACS), the most lethal 
manifestation of ischemic heart disease, remains challenging. Due to limitations 
in the diagnostic accuracy and costs associated with current methods for 
diagnosing ACS, evaluating patients for ACS in the emergency department (ED) 
can last up to 24 hours. The consequences of such prolonged ED evaluation are: 
high personal cost to the patient, significant financial costs to the healthcare 
system (estimated at $3 to $4 billion annually), and additional strain on an 
already overstretched emergency medical care system.  
Measurement of circulating levels of cardiac troponin (cTn) is central to 
the diagnosis of acute myocardial infarction. Recent advances in clinical 
chemistry have yielded significant improvements in the analytic performance of 
cardiac troponin assays (cTn), resulting in superior sensitivity and precision. 
These high sensitivity cTn  (hsTn) assays are able to detect up to ten-fold lower 
concentrations of cTn than current generation cTn, resulting in earlier diagnosis 
of acute myocardial infarction (AMI), reclassification of some unstable angina 
patients as AMI and shortened duration of the rule out AMI period for some 
patients. However, they also result in an increase in the number of non-ACS 
patients who will have elevated hsTn values, amplifying the clinical challenge of 
determining which patients with elevated cTn warrant inpatient admission versus 
outpatient management. There are insufficient data to guide the use of hsTn for 




Chapter 1 is an introductory chapter that discusses the current paradigm 
of ACS evaluation in the emergency department (ED), and the promise and 
challenges associated with clinical use of hsTnI to diagnose ACS in the ED. 
Chapter 2 is a prospective cohort study that quantifies for the first time in an ED 
located in the United States of America (USA), the frequency and prognostic 
implications of new cTn elevations when a high sensitivity troponin I (hsTnI) 
assay is used. This chapter also characterizes factors associated with new cTn 
elevations and explores the effects of these new elevations on potential hospital 
admissions. Chapter 3 is a cross-sectional study that examines the frequency 
and determinants of high sensitivity troponin I (hsTnI) values in emergency 
department (ED) patients with a primary non-cardiac diagnosis. Chapter 4 is a 
cross-sectional study that determines whether hsTnI can be used as a screening 
test to identify suspected ACS patients who do not have significant coronary 
artery stenosis (candidates for early discharge). In the concluding chapter 5, I will 
discuss future directions of this work and propose a new paradigm for evaluating 
ACS in the ED using hsTnI.  
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Diagnosing acute coronary syndrome 
Timely diagnosis of acute coronary syndrome (ACS) in the emergency 
department remains challenging. Each year, about 5-7 million visits are made to 
emergency departments (ED) across the United States for chest pain and other 
symptoms concerning for acute coronary syndrome (ACS).1,2 ACS, the most 
lethal manifestation of ischemic heart disease, occurs when there is acute 
disruption of coronary blood flow, leading to a mismatch between myocardial 
oxygen demand and supply, and ultimately resulting in myocardial ischemia and 
infarction.3,4  The term ACS encompasses acute myocardial infarction (AMI) 
comprised of ST elevation myocardial infarction (STEMI) and non-ST elevation 
myocardial infarction (NSTEMI) , and unstable angina (UA).5  
Initial diagnostic testing for ACS begins with an ECG (Figure 1.1). However, 
the sensitivity of the initial ECG for diagnosing AMI has been reported to be as 
low as 40-50%.6,7 Even when used in combination, history and physical 
examination, initial ECG, cannot reliably exclude ACS.8 Thus, suspected ACS 
patients with non-diagnostic ECGs undergo additional testing including serial 
biomarker measurements. In fact, the current definition of AMI is based on 
biomarker (cardiac Troponin [cTn]) measurements. The 2012 “universal 
definition” of AMI according to Global AMI Task force (endorsed by the European 
Society of Cardiology (ESC), the American College of Cardiology Foundation 
(ACCF), the American Heart Association (AHA), and the World Heart Federation 




values (preferably cTn) with at least one value above the 99th percentile upper 
reference limit (URL) and with at least one of the following: 
• Symptoms of ischemia. 
• New or presumed new significant ST-segment–T wave (ST–T) changes or 
new left bundle branch block (LBBB). 
• Development of pathological Q waves in the ECG. 
• Imaging evidence of new loss of viable myocardium or new regional wall 
motion abnormality. 
• Identification of an intracoronary thrombus by angiography or autopsy. 
Patients with ECG and serial troponin measurements that are non-diagnostic for 
AMI, but have new onset or severe exertional angina (Canadian Cardiovascular 
Society grade III or higher10) are classified as having unstable angina. However, 
with recent improvements in the sensitivity of cTn assays this category of 
patients is becoming vanishingly small.11 
The biology of cardiac troponins  
The troponin complex, consisting of three structural proteins (Troponin C 
[TnC], Troponin I [TnI] and Troponin T [TnT]), plays an integral part in the 
contraction of cardiac and skeletal muscle but not smooth muscle. Muscle 
contraction occurs when intracellular calcium ions increase and bind to the high 
affinity calcium-binding site TnC, resulting in conformational changes in TnT and 
TnI. TnT binds to tropomyosin, which facilitates the formation of cross bridges 




actin-tropomyosin and prevents contraction in the absence of calcium binding 
(which is released when it binds to calcium-TnC resulting in crossbridge 
formation and contraction).   
Human cTnT is a 38 kDa protein comprising of 298 amino acid residues, 
whereas cTnI is approximately 23 kDa and is made up of 210 amino acid 
residues, and cTnC is an 18 kDa protein made up of 161 amino acid residues.13 
Cardiac troponin C (cTnC) is identical to skeletal slow troponin C (sTnC) 
although distinct from skeletal fast cTnC, hence it is not a useful biomarker of 
myocardial disease. cTnT and cTnI are unique isoform that is only expressed in 
cardiac, while slow and fast skeletal muscle have their associated isoforms 
(cTnT, cTnI, ssTnT, ssTnI, sfTnT and sfTnI, respectively ).14 TnT is also 
complicated by the existence of a number of splice variants that can be 
expressed differentially.  Importantly, there is 56.6% and 58.3% homology 
between cTnT and fsTnT and ssTnT respectively.15 Cardiac (cTnI), fast-twitch 
skeletal muscle (fast cTnI)  and slow-twitch skeletal muscle (slow cTnI) isoforms 
have  about 40% amino acid sequence homology, and in particular cTnI have an 
32 amino acid N-terminal extension that not present in either skeletal isoforms.15 
As a result, antibodies used in clinical enzyme-linked immunosorbent assay 
(ELISA) assays for cTnT and cTnI are selected based on their ability to recognize 
epitopes that have no sequence homology with skeletal TnI or TnT. However, 
there are still reports of falsely elevated cTnT secondary to diseased skeletal 
muscle, despite the use of fourth generation and high sensitivity cTnT assays.16 




release of cTn, followed by a continuous release of cTn from disintegrating 
myocytes that occurs during myocyte necrosis (or potentially other cell death 
mechanisms).17 It is worth noting that myocyte necrosis is not a requirement for 
troponin release.18 Other factors such as cellular apoptosis, normal myocyte 
turnover,19 preload induced caplain-mediated proteolysis,20 integrin-mediated 
increased cellular wall permeability,21 and formation and release of 
membraneous blebs.22   
Rationale for serial measurements of cardiac troponins  
cTnI or cTnT can be measured in serum by ELISA within 1-6 hours of 
onset of myocardial injury (or cellular membrane disruption).23 Despite recent 
improvements in the sensitivity of cardiac troponin assays approximately 10-20% 
of patients with AMI have a negative cTnI or cTnT on presentation.24,25 The 
mechanisms underlining NSTEMI patients with initial cTnI negative are likely 
related to the following: short time interval between onset infarction and ED 
presentation or blood draw;24,26 incomplete occlusion of coronary vessels;27 and 
conversion from unstable angina to NSTEMI after presentation.26 Cullen et al. 
recently demonstrated that a combination of clinical characteristics and ECG 
findings can rule-out AMI patients in a subset of patients.28 Although the optimal 
timing of serial cTn measurements remains unclear, it remains unlikely that a 
single criterion will be applicable to all patients. The optimal timing of serial cTn 
measurements will depend on assay characteristics, time of onset of symptoms, 
whether symptoms are constant or intermittent, and other evidence of ischemia 




All troponin assays are not equal 
Circulating troponin exists as a mixture of complex (trimer, dimer) and free 
monomers (or bound to other circulating proteins) 29,30as the intact and modified 
forms including degraded, phosphorylated/un-phosphorylated, glycosylated, 
acetylated and oxidized/unoxidized forms; among others. Post-translational 
modifications of cTnI and cTnT (including selective degradation) occurs 
predominantly in the myocardium in response to ischemia, leading to a high 
number of modified cTn products31 32 (See Figure 1.2).  In a study of patients 
with AMI, a cTnI degradation product was identified as early as 90 minutes after 
onset of symptoms.33 Up to 11 cTnI degradation products have been identified in 
AMI patients.34 During ischemia, proteolysis of the C-terminal of cTnI occurs, 
followed by N-terminal proteolysis cleavages that subsequently occur with 
increasing degree of ischemia. Furthermore, numerous studies have 
demonstrated that cTn can be phosphorylated at multiple amino acid residues 
with resulting alterations in function.35-37 Zhang et. al. demonstrated that selective 
and functionally significant phosphorylation alterations occur on individual 
residues of cTnI in heart failure.38 The clinical implications of cTn 
phosphorylations are not well understood. Although several of the novel sites 
were identified by Zhang et. al., they have not yet been investigated for their 
functional affects.  The above mentioned post-translational modifications of cTn 
may affect its immunoreactivity and hence the results of cTn ELISA assays.  
Although standardization or harmonization of the various cTnI clinical ELISA 




obtained may not reflect the ‘True” concentration for a particular individual .  
Owing to patent restrictions, cTnT assays are available from one company 
(Roche) and the current generation of cTnT assays (fifth generation) have been 
approved for clinical use in Europe. Like cTnI, cTnT also has known proteolytic 
and phosphorylation and other PTMs, which could affect this ELISA cTnI assays 
have been developed by a number of different manufacturers including: Abbott 
Laboratories, Beckman Coulture, Siemens, Singulex, Nanosphere, Ortho Clinical 
Diagnostics among others.39 Each manufacturer uses their own set of proprietary 
antibodies and reference standards. Thus, cTnI values using assays from 
different manufacturers are not comparable. A first step towards cTnI 
standardization would involve a universal adoption of capture and detection 
antibodies.40  Thus, the value obtained for each assay will depend on the exact 
epitopes of the two anti-cTnI antibodies and the amount of TnI or TnI fragments 
which contain both epitopes. Thus, if proteolysis or another PTM eliminates on 
the availability of one of the epitopes, it will not be measured. This extent to 
which this occurs will vary for each individual and for each assay.  
High sensitivity troponin:  the new generation of troponin assays. 
Recently, clinicians have begun to use the recommended cut-off values 
for current generation cardiac troponin assays; the 99th % upper reference limit 
(URL). Previously, there was reluctance to use these cut off values because they 
are associated with frequent elevations in cTn not associated with acute ischemic 
heart disease (such as: tachy/brady arrhythmias, cardiac structural abnormalities, 




cardiotoxic agents, heart failure among others9). Thus there was a tendency to 
use cut-off values for troponin that equated with the prior gold standard diagnosis 
developed with less sensitive markers such as creatine kinase MB isoenzyme 
(CKMB) or the lowest value at which assay achieved a 10% co-efficient of 
variation (CV) which was thought to reduce false positive elevations.  The use of 
the 99th% URL increases the ability of these assays to detect both acute 
myocardial infarction and structural cardiac morbidities.41  This change in practice 
should not be confused with increasingly sensitive assays. 
Preparing the United States for High Sensitivity Cardiac Troponin Assays 
Manuscript:  
Korley, FK and Jaffe AS.  
Published in J Am Coll Cardiol. 2013 Apr 30;61(17):1753-8. 
Improvements in the analytic performance of cardiac troponin assays 
(cTn) have resulted in superior sensitivity and precision. Improved sensitivity 
occurs because of more sensitive antigen binding and detection antibodies, 
increases in the concentration of the detection probes on the tag antibodies, 
increases in sample volume, and buffer optimization.15  Assays now are able to 
measure 10-fold lower concentrations with high precision [a co-efficient of 
variation (CV) <10% at the 99th % of the upper reference limit (URL)]. The high 
sensitivity cTnT (hs-cTnT) assay is already in clinical use throughout most of the 
world.  It is only a matter of time before high sensitivity assays are approved for 




issues that deserve consideration. They will be helpful as well with the use of the 
99th% URL with contemporary assays.   
The need for a universally accepted nomenclature. 
The literature is replete with terminologies used to refer to cTn assays. We 
advocate the use of the term “high sensitivity cardiac troponin assays” (hs-cTn) 
for cTn assays that measure cardiac troponin values in at least 50% of a 
reference population.15,42 This is a policy we are informed has now been 
embraced by the journal Clinical Chemistry. High sensitivity assays can be 
further categorized as well. 
Ideally, assays should have a CV of <10% at the 99th % value. Assays that 
do not achieve this level are less sensitive. However, they do not cause false 
positives and they can be used.43  
Defining uniform criteria for reference populations  
There is a lack of consistency in the types and numbers of subjects that 
should/can constitute a reference population.15 Often, participants are included 
after simple screening by check list but without a physical examination, 
electrocardiogram, or lab work. At other times, a normal creatinine and/or a 
normal natriuretic peptide value is required. Imaging to detect structural heart 
disease is rarely used. It is known that gender, age, race, renal function, heart 
failure and structural heart disease, including increased left ventricular (LV) mass 
are associated with increased cardiac troponin concentrations, 44-46 and that an 
assay’s 99th % value depends on the composition of the reference group. Thus, 




appropriate reference value to use clinically also is far from a settled issue. It 
might be argued that using a higher 99th % value for the elderly allows 
comparison of the patient to his/her peers but in raising the cut off value, if the 
increases are due to comorbidities, those who are particularly healthy will be 
disadvantaged.47 Gender and ethnicity are not comorbidities and we would urge 
should be taken into account. It is clear that regardless of the assay, there will 
need to be different 99th% values for men versus women.15 The reference 
population for assay validation studies should ideally be based on demographic 
characteristics that mirror the United States population and include subjects 
whose blood pressure, serum glucose, creatinine and natriuretic peptide values 
are within the normal reference range and who take no cardiac medications. 
These subjects should be free from structural heart disease documented by 
echocardiography, cardiac MRI or CT angiography. Meeting these criteria will be 
a major challenge especially for older individuals although some initial studies 
have been performed.48  A conjoint pool of samples collected with the support of 
commercial manufacturers so that all companies could use the identical patient 
population for their reference ranges would be a major advance. One large 
national effort would probably be more cost effective than multiple smaller efforts. 
Regardless of reference values, solitary elevations of hs-cTn values (>99th 
%) will be inadequate for clinical decision making.49 The exception may be very 
elevated values which are most often due to myocardial infarction or myocarditis 




changes in hs-cTn values will be required to determine whether acute myocardial 
injury is present.  
Discriminating acute from non-acute causes of hs-cTn elevations 
With the ability to precisely measure small concentrations of cTn clinicians 
will be faced with the challenge of discriminating between patients who have 
acute problems from those with chronic elevations from other etiologies. Using 
the 4th generation cTnT assay, approximately 1% of patients in the general 
population in the US have modest elevations >99th% URL.50 In the same 
population, this number was 2% with the hsTnT assay.45 Of that number, only 
half had documentation (even with imaging) of cardiac abnormalities.  If the 
prevalence of a positive cTnT is 2% in the general population, it will likely be 10 
or 20% in the ED and even higher in hospitalized patients, since these patients 
often have cardiac comorbidities.  
Measurement of changes in hs-cTn over time (δ hs-cTn) improves the 
specificity hs-cTn for the diagnosis of acute cardiac injury.51,52 However, it does 
so at the cost of sensitivity.  With contemporary assays, differences in analytical 
variation have been used to define an increasing pattern. At elevated values, the 
coefficient of variation (CV) for most assays is in the range of 5-7% so a change 
of 20% ensures that a given change is not due to analytical variation alone.49 At 
values near the 99th % URL, higher change values are necessary.52 The situation 
with hs-cTn assays is much more complex: 




2. It will be easy to misclassify patients with coronary artery disease who 
may present with a non-cardiac cause of chest pain but have elevated 
values.  They could be having unstable ischemia or elevations due to 
structural cardiac abnormalities and non-cardiac discomfort. If hs-cTn 
is rising significantly, the issue is easy but if the values are not rising, a 
diagnosis of AMI still might be made. If so, some patients may be 
included as having AMI without a changing pattern. This occurred in 
14% patients studied by Hammarsten et al.53 If patients with elevated 
hs-cTn without a changing pattern are not called AMI, should they be 
called patients with “unstable angina and cardiac injury” or patients 
with structural heart disease and non-cardiac chest pain? Perhaps 
both exist? 
3. The release of biomarkers is flow dependent. Thus, there may not 
always be rapid access to the circulation. An area of injury distal to a 
totally occluded vessel (when collateral channels close) may be 
different in terms of the dynamics of hs-cTn change than an 
intermittently occluded coronary artery. 
4. Conjoint biological and analytical variation can be measured. They are 
assay dependent and the reference change values (RCV) range from 
35%-85%.15 The use of criteria less than that (which may be what is 
needed clinically) will thus likely include individuals with changes due 




shown to be the case in many patients with non-acute cardiovascular 
diagnoses.53,54   
5.  Most evaluations have attempted to define the optimal delta, often with 
receiver operator curve analysis. Such an approach is based on the 
concept that sensitivity and specificity deserve equivalent weight. But 
higher deltas improve specificity more and lower ones improve 
sensitivity and it is not clear that all physicians want the same tradeoffs 
in this regard. ED physicians often prefer high sensitivity so that their 
miss rate is low (<1%), 55 whereas hospital clinicians want increased 
specificity. This tension will need to be addressed in defining the 
optimal delta. 
6.  The delta associated with AMI may be different from that associated 
with other cardiac injury.53 In addition, women have less marked 
elevations of cTn in response to coronary artery disease56 and in 
earlier studies were less apt to have elevated values.57 Given their 
pathology is at times different, it may be that different metrics may be 
necessary based on gender.  
7.  Some groups have assumed that if a change is of a given magnitude 
over 6 hours, it can be divided by 6 and the one hour values can be 
used. This approach is not data driven and biomarker release is more 
likely to be discontinuous rather than continuous.58  In addition, the 
values that one obtains with this approach are too small to be 




These issues pose a major challenge even for defining the ideal delta 
change value and provide the reasons why the use of this approach will reduce 
sensitivity.59,60 
In addition, there is controversy in regard to the metrics that should be 
used with high sensitivity assays. The Australian-New Zealand group proposed a 
50% change for hs-cTnT for values below 53 ng/L and a 20% change above 
that.61 The 20% change is much less than conjoint biological and analytical 
variation. A number of publications have suggested the superiority of absolute δ 
cTn compared to relative δ cTn, in discriminating between AMI and non-AMI 
causes of elevated cTn.62-64 However, the utility of the absolute or relative δ cTn 
appears to depend on the initial cTn concentration and the major benefit may be 
at higher values.62 A recent publication by Apple et al calculates deltas in several 
different ways with a contemporary assay and provides a template for how to do 
such studies optimally.65 If all studies were done in a similar fashion, it would help 
immensely. In the long run, institutions will need to define the approach they wish 
to take. We believe this discussion is a critical one and should include 
Laboratory, ED and Cardiology professionals. 
Distinguishing between Type 1 and Type 2 AMI. 
Although  δ cTn is helpful in distinguishing between AMI and non-acute 
causes of troponin release, it may or may not be useful in discerning type 1 from 
type 2 AMI. As assay sensitivity increases, it appears that the frequency of type 2 
AMI increases.  However, making this distinction is not easy. Type 1 AMI is due 




aggressive anticoagulation, and revascularization (percutaneous coronary 
intervention or coronary artery bypass).49 Type 2 AMI, typically evolves 
secondary to ischemia from an oxygen demand/supply mismatch such as severe 
tachycardia, hypo or hypertension and the like with or without a coronary 
abnormality. These events usually are treated by addressing the underlying 
abnormalities. They are particularly common in patients who are critically ill and 
those who are postoperative.66 However, autopsy studies from patients with post-
operative AMI often manifest plaque rupture.67 Thus, the more important events, 
even if less common, may be type 1 AMIs. Type 2 events seem more common in 
women who tend to have more endothelial dysfunction, more plaque erosion and 
less fixed coronary artery disease.67-69 Additional studies are needed to 
determine how best to make this clinical distinction. For now, clinical judgment is 
recommended. 
Analytical imprecision in cardiac troponin assays 
All analytical problems will be more critical with hs-cTn assays. cTnI and 
cTnT are measured using Enzyme Linked Immunosorbent Assays (ELISA). As 
with all immunoassays, quantification of hs-cTn can be influenced by 
interferences between reagent antibodies and the analyte (cTn) leading to false 
positive or negative results.70   Auto-antibodies to cTnI or cTnT are found in 5%-
20% of individuals and can reduce detection of cTn 71,72 Additionally, fetal cardiac 
troponin isoforms can be re-expressed in diseased skeletal muscle and detected 
by the cTnT assays resulting in false positive values.73 Several strategies 




fragments have been employed to reduce interferences.74 However, these 
strategies do not completely eliminate them. Furthermore, there are differences 
in measured cTn values based on specimen type (serum versus heparinized 
plasma versus EDTA plasma)75. In addition, hemolysis may affect the accuracy 
of cTn measurement on some platforms 76 and it is hard to avoid especially with 
line draws which are common especially in intensive care units. 
Ruling Out AMI 
Studies evaluating the diagnostic performance of hs-cTn assays for the 
early diagnosis of AMI usually define AMI on the basis of a rising and/or falling 
pattern of current generation cTn values.60,77 However, defining AMI on the basis 
of the less sensitive current generation assay, results in an underestimation of 
the true prevalence of AMI and an overestimation of negative predictive value of 
the experimental assay. It also shortens significantly the time it takes to rule in all 
the AMIs and thus to definitively exclude AMI since it ignores the new AMIs more 
sensitively detected by the hs-cTn assay. Thus, in the study by Hammarsten  et 
al,53 the time to exclude all AMIs was 8.5 hours when all of the AMIs detected 
with the high sensitivity assay were included whereas others that do not include 
these additional events report this can be done in 3-4 hours60,68,77. In our view, 
Hammarsten is correct.    
This does not mean that hs-cTn cannot help in excluding AMI. Body has 
reported that patients who present with undetectable values (<than the LOB of 
the hs-cTnT assay) were unlikely to have adverse events during follow up. If one 




significant proportion of patients with possible ACS could have that diagnosis 
excluded with the initial value.  Studies need to continue to evaluate cTn values 
for at least 6 hours to define the frequency of additional AMIs detected in that 
manner. Using follow-up evaluations of patients with small event rates who are 
likely to have additional care during the follow-up period are likely to be 
underpowered. It may be that better up front risk stratification may help with this 
as recently reported.55,79 Low risk patients who have good follow-up after ED 
visit, may be a group that can be released as early as 2 hours after 
presentation.55 
Investigating the etiology of positive troponin values in non-AMI patients 
Elevated troponin values (including those with high sensitivity assays) are 
associated with a 2 fold higher risk for longer term all-cause mortality and 
cardiovascular death than a negative troponin.45,80-82 This association is dose-
dependent.  If values are rising, they are indicative of acute cardiac injury. Those 
patients should be admitted because the risk is often short term. However, if the 
values are stable, assuming the timing of any acute event would allow detection 
of a changing pattern, the risk, though substantive, in our view, often plays out in 
the longer term.82 Many of these individuals, assuming they are doing well 
clinically can be evaluated outside of the hospital in our view. However, because 
such elevations are an indicator of a subclinical cardiovascular injury such 
evaluations should be early and aggressive. The data from several studies 




evolve that patients in the upper ranges of the normal range also require some 
degree of cardiovascular evaluation.   
Risk stratifying patients with non-Acute Coronary Syndrome conditions 
Patients who have a rising pattern of values have a higher risk of mortality 
than those with negative values regardless of the etiology. Investigations are 
ongoing to determine how well results from high sensitivity troponin testing help 
risk stratify patients with pulmonary embolism,83 congestive heart failure,84 
sepsis,85 hypertensive emergency86, and chronic obstructive pulmonary 
disease87. At present, they suggest that troponin values classify patients into 
clinically relevant risk-subgroups. Studies are needed to evaluate the incremental 
prognostic benefit of high sensitivity cardiac troponin.  
CONCLUSION 
Routine use of hs-cTn assays in the United States is inevitable. These 
assays hold the promise of improving the sensitivity of AMI diagnoses, 
shortening the duration of AMI evaluation and improving the risk stratification of 
other non-cardiac diagnoses. However, to be able to fully realize their potential, 
additional studies are needed to address the knowledge gaps we have identified. 
In the interim, clinicians need to learn how to use the 99th% URL and the concept 
of changing values so when the day comes that hs-cTn assays are available, 




















Figure 1.3: Relationship between patient characteristics and the 99% URL 


























, but did 
not meet stringent BP, fasting 
glucose, GFR, or echocardiogram 
criteria 
Healthy individuals who have 
comorbidities and hence did not 
pass questionnaire screen 
a = No history of vascular disease or diabetes, and not taking cardioactive drugs 
b = No history of vascular or cardiovascular disease, diabetes, hypertension, heavy alcohol intake, or 
cardiac medications AND had blood pressure <140/90mmHg; fasting glucose <110mg/dL; eGFR 
>60mL /min; LVEF > 50%; normal lung function; and no significant abnormalities on 
echocardiography. 






























Figure 1.4: Defining the optimal delta: tension between sensitivity and 
specificity 
 

































Chapter 2: Previously Unrecognized Elevations of High Sensitivity Cardiac 
Troponin I in the Emergency Department: How Frequent and How Important 
are They? 
Korley FK, Schulman SP, Sokoll LJ, Stolbach AI, DeFilippis AP, Bayram JD, 
Omron R, Post WS, Fernandez C, Lwin A, Cai SS, Jaffe AS 
Abstract 
Objectives: Our aims were to quantify the prevalence of elevated high-sensitivity 
troponin I (hsTnI) in emergency department (ED) patients without elevated 
standard troponin I (cTnI), and to determine the association of these previously 
unrecognized hsTnI elevations with subsequent admission for a cardiac 
diagnosis and all-cause mortality. 
Design: Prospective observational study 
Setting: An urban ED that is part of a tertiary care academic institution. 
Patients: ED patients evaluated for suspected acute coronary syndrome (ACS) 
Interventions: HsTnI (Abbott) and cTnI (Beckman Coulter) levels were 
measured in 815 ED patients with chest pain, dyspnea or clinical suspicion for 
ACS.  Treating clinicians were blinded to hsTnI measures. 
Main outcome measures: Previously unrecognized hsTnI elevation (defined as 
hsTnI>99th% in a subject without a cTnI elevation on the initial sample). 
Secondary outcome was a composite of hospitalization for a cardiac diagnosis 




Results: The prevalence of previously unrecognized hsTnI on the initial sample 
was 10.5% (75/717) using a gender-neutral cut-off for the 99th%, and 12.7% 
(91/717) using a gender-specific cut-off. Patients with previously unrecognized 
hsTnI elevation were at higher risk for subsequent hospitalization for a cardiac 
diagnosis and all-cause mortality during the 1 year period following index 
discharge (Hazard Ratio 3.35 [95% CI: 2.22 – 5.05]) than those with no cTnI and 
hsTnI elevation. Additionally, their risk for subsequent hospitalization for a 
cardiac diagnosis and all-cause mortality was similar to those who had both cTnI 
and hsTnI elevations. The adjudicated diagnoses of patients with previously 
undetected hsTnI elevations (gender-neutral cut-off) were: 3 (4.0%) ACS, 15 
(20.0%) acutely decompensated heart failure (ADHF) or 3 (4.0%) volume 
overload etiology unclear/non-cardiac, 4 (5.3%) cardiac (non-ACS), and 50 
(66.7%) other.  
Conclusions: With the use of the Abbott HsTnI, 10.5 – 12.7% of patients with 
previously unrecognized cTnI elevation (Beckman Coulter) had hsTnI elevations 
on the initial sample. Although only 4% were determined to have ACS, these 
patients were at higher risk for subsequent hospital admission for a cardiac 






High sensitivity cardiac troponin (hsTn) assays88,89 including the novel hsTnI 
assay from Abbott are currently available for routine clinical use in Europe. Their 
use increases the proportion of non-ST myocardial infarctions (NSTEMI) that will 
have increased troponins at presentation,25,90 and allows for novel ways of ruling 
out myocardial infarction (AMI).28,91  However, hsTn assays also detect 
myocardial injury from many other disease conditions.  Thus, clinicians will be 
challenged to determine the management and disposition of many more patients 
with cardiac injury. The frequency of this problem, the factors that lead to it and 
the prognosis associated with it are in part, assay and population dependent.  
The novel hsTnI assay from Abbott has been available since January 2013.  It 
detects far more normal individuals than the hsTnT assay39 and thus by that 
metric is more sensitive.  There are very few data using this potentially more 
sensitive assay in ED patients.  The selection of ED patients needing biomarker 
evaluation to rule out AMI varies according to geographic location, the size of the 
facility involved, and the needs of a given hospital but prior studies with hsTnT 
were performed in larger centers with pre-selected ED populations with high 
prevalence of AMI.25,90,91 Therefore studies are needed in more heterogeneous 
ED populations, to better understand the impact of hsTn assays in general and 
specifically this new putatively sensitive assay.  Thus, we sought to quantify the 
frequency of these previously undetected elevations and determine whether 




subsequent hospital admission for a cardiac condition (after index discharge) 
than those with non-elevated troponin values.  
Methods 
Study design, setting and participants 
A prospective observational study of patients evaluated for suspected acute 
coronary syndrome (ACS) was conducted after approval by the institutional 
review board. The study was conducted at an urban ED that sees 65,000 
patients yearly and is part of a 1,000 bed academic, tertiary care institution. 
Patients with non-diagnostic initial ECGs, a chief complaint of chest pain or 
shortness of breath and cTnI ordered by treating clinicians were eligible. Such 
patients are routinely evaluated for possible AMI at our institution.  In addition, 
patients with other complaints who had serial cTnI testing were eligible if their 
physicians confirmed that ACS was suspected. Written informed consent was 
obtained. Enrollment of patients occurred on weekdays from 9:00 am to 9:00 pm. 
Patients were excluded if they had ST elevation myocardial infarction (STEMI), 
left against medical advice, or if an initial blood sample was not obtained.  
Data and sample collection 
Research assistants interviewed subjects and their clinicians, and collected 
demographic and clinical information which was entered into a database via an 
online collection tool. 92  Blood samples were obtained at presentation and every 
3 hours as dictated by the clinical care of the patient.  Samples were centrifuged, 




hospital’s cTnI assay (Beckman Coulter,Chaska, MN) Access II AccuTnI assay 
was used for clinical care. The 99th% upper reference limit (URL) for this assay is 
40ng/L.  The co-efficient of variation (CV) for this assay is 14% at 40ng/L: the 
10% CV value is 60ng/L. Our clinical laboratory only reports values of 
cTnI>60ng/L (the decision making cut-off for the institution). hsTnI was measured 
in batches using the Abbott Laboratories’ (Abbott Park, IL) research-use 
ARCHITECT STAT hsTnI assay. The 99th% URL is 34.2ng/L for males, 15.6ng/L 
for females and 26.2ng/L overall.  The limit of detection (LOD) is 1.2ng/L.93 hsTnI 
data were used for research purposes only.  
Estimated glomerular filtration rate was calculated from enzymatic creatinine 
results (Roche Modular and Cobas c701, Roche Diagnostics, Indianapolis, IN) 
and the IDMS-traceable 4-variable Modification of Diet in Renal Disease 
equation.            
Outcomes and Definitions 
An elevated local cTnI was defined as a value >60ng/L. An elevated hsTnI value 
was defined as >26.2ng/L.  Gender-specific cutoff values were probed as well. 
We defined a previously unrecognized hsTnI elevation as an hsTnI>99th% in a 
subject with cTnI <60ng/L.   
Clinical outcomes were adjudicated by a committee comprised of five board 
certified emergency physicians and two board certified cardiologists. ED 
physician reviewers blinded to hsTnI data reviewed all clinical information 
available and assigned the appropriate diagnosis. Disagreements between the 




cardiology arbitrator. AMI was defined according to the universal definition of 
AMI, except for the cTnI cutoff imposed at our institution.49  A significant rising 
and/or falling pattern in the local cTnI values was defined as a change of at least 
30% at the 10% co-efficient of variation level (18 ng/L or greater within 6-9 
hours).63 Unstable angina was defined based on the clinical history, objective 
ECG findings, a positive stress test or coronary artery stenosis on CT coronary 
angiography or coronary angiography catheterization of 70% or greater.  Acutely 
decompensated heart failure (ADHF) was defined using modified Framingham 
criteria.94 Patients with radiographic or clinical evidence of volume overload 
suspected from non-cardiac conditions such as end-stage renal disease were 
classified as volume overload, etiology unclear/non-cardiac. Patients diagnosed 
with myocarditis, pericarditis, valvular disorders and arrhythmia were classified 
as: cardiac (non-ACS).   
A separate analysis was done with the investigational hsTnI assay (blinded to the 
cTnI assay), using criteria proposed by the ESC task force.95 Patients diagnosed 
with unstable angina were considered to have NSTEMI if hsTnI values were 
elevated with a rising and/or falling pattern and a >20% change in the initial hsTnI 
within 3 hours (if the initial hsTnI was > URL) or a change of at least 50% of the 
URL within 3 hours if the initial hsTnI was < URL.  
We determined the time to the first occurrence of a composite of adverse events 
(death, or hospital admission for ACS, revascularization, ADHF or tachy/brady 
arrhythmia) during the year following index ED/hospital discharge. Hospital 




interview was conducted at least 30 days and 1 year after index ED/hospital 
discharge. For patients in whom follow-up could not be completed via phone or 
chart review, we queried the Social Security Death Master File 
(http://www.ssdmf.com) on August 30th, 2013, to ascertain their mortality status 
at 1 year after ED/hospital discharge.  
Statistical Analysis 
Differences between proportions were assessed with a χ2 test. The frequency of 
elevated hsTnI was evaluated based on gender-neutral and gender-specific 
cutoffs for the 99th%.  We also calculated 3 and 6 hour absolute and relative 
changes in hsTnI. To examine the association between hsTnI elevation and time 
to the first occurrence of an adverse event, we performed survival analyses using 
Cox proportional hazards models. We chose the day of discharge from the 
ED/hospital during the index visit as the origin, and follow-up time in days as the 
time metric. For all survival analyses, the proportionality assumption of the Cox 
model was confirmed by inspection of log(-log[survival function]) curves and 
Schoenfeld residuals. A two-tailed p-value of <0.05 was considered statistically 
significant. Statistical analyses were performed using STATA/MP statistical 
software version 11.2 (StataCorp, College Station, Texas), and RStudio 
statistical software version 0.97.312. Assuming the prevalence of new cTnI 
elevation is 9.0%, studying 815 patients allowed us to estimate the true 
prevalence within a +2% confidence interval. 
Results 




Between January 20th 2012 and July 31st 2012, 815 subjects were enrolled 
(Figure 2.1). Demographic characteristics of enrolled subjects and subjects with 
a troponin order, who presented on weekends or after 9pm on weekdays, during 
the same time period (Supplemental Table 2.2) were similar. The adjudicated 
final diagnoses are shown in Table 2.2.  No patients initially diagnosed as having 
unstable angina were reclassified as having NSTEMI based on the hsTnI data. 
Frequency of previously unrecognized hsTnI elevation 
In the initial sample, 92.8% (756/815) of our study population had detectable 
hsTnI.   20.4% (166/815) had an elevated hsTnI (gender-neutral cutoff for the 
99th%) and 22.0% (179/815) had elevated hsTnI (gender-specific cutoff for 
99th%).  With the local assay, only 12.0% (98/815) had an elevated cTnI in the 
initial sample.  Thus, the frequency of previously unrecognized hsTnI elevation at 
presentation was 10.5% (75/717) with the gender-neutral cutoff, and 12.7% 
(91/717) with the gender-specific cutoffs.  Patients with volume overload either 
from ADHF or from unclear/non-cardiac etiology had the highest frequency of 
previously unrecognized hsTnI elevation (Table 2.2). Similarly patients with a 
chief complaint of shortness of breath had the highest frequency of previously 
unrecognized hsTnI elevation (Table 2.3). Depending on the cut-off used for the 
99th%, 11.8 – 17.6% ACS patients who previously had unrecognized cTnI 
elevation on the initial sample, had elevated hsTnI on initial measurement (Table 
2.2). 
Notably, 0.9% (7/815) had elevated cTnI but no hsTnI elevation. Six of these 




change (delta) of 10ng/L or less. The remaining patient had an initial cTnI of 
329ng/L, and no change in cTnI in serial measurement. This patient had mild 
coronary artery disease on cardiac catheterization. 
Adverse events during the year following ED/hospital discharge. 
During the year following ED/hospital discharge, there were a total of 89 (11.0%) 
deaths and 87 (10.7%) hospital admissions for a cardiac condition (55 ADHF, 10 
tachy/brady arrhythmia, 9 NSTEMI medically managed, 8 AMI with 
revascularization, 5 Unstable angina). Twenty-seven subjects were hospitalized 
for a cardiac condition prior to dying during the follow-up period. Four patients 
died during the index hospital admission and were excluded from the survival 
analyses. Subjects with previously unrecognized hsTnI elevation were at higher 
risk of having an adverse event during year following ED/hospital discharge than 
those with both un-elevated cTnI and hsTnI (hazard ratio: 3.35 [95% CI: 2.22 – 
5.05]). Additionally, subjects with previously unrecognized hsTnI elevation had a 
similar risk of adverse events during follow up as those with both elevated cTnI 
and hsTnI (hazard ratio: 3.18 [95% CI: 2.12 – 4.78]). Kaplan Meier curves for the 
occurrence of adverse events during follow-up are presented in Figure 2.3.  
Changes in hsTnI on serial measurement 
Among enrolled subjects 76.1% (620/815) had serial cTnI measurement and 
58.3% (475/815) had serial hsTnI measurements at 3 or 6 hours. Of the subjects 
with a previously unrecognized hsTnI elevation [gender-neutral cutoff] and no 
ACS, the median 3-hour relative change change in hsTnI was 9.1% (95%CI:5.4–




on the ESC taskforce definition95, 2.4% (8/337) of subjects diagnosed with “other 
diagnosis” who had serial samples, had a significant rise and or fall in hsTnI of 
20% (or 50% if the initial hsTnI was<URL) at 3 hours. 
Sensitivity analyses 
We conducted a number of analyses to determine whether our results were 
influenced by our definition of previously unrecognized cTnI elevation. First, 
previously unrecognized cTnI elevation was redefined non-elevated cTnI on the 
initial, 3, 6 and 9 hour samples who had elevated hsTnI on the initial sample. In 
this analysis, the prevalence of previously unrecognized hsTnI elevation was 
8.8% (61/692). Secondly, we compared the Abbott cTnI (instead of the Beckman 
cTnI) to the Abbott hsTnI assay. In this analysis, the frequency of previously 
unrecognized hsTnI elevation was 9.3% (65/702). There were 7 patients with 
insufficient sample for Abbott cTnI measurement. In both analyses, subjects with 
previously unrecognized hsTnI were at higher risk of adverse events than those 
with both non-elevated cTnI and hsTnI. Additionally, their risk for adverse events 
was similar to subjects with both elevated cTnI and hsTnI (Table 2.4). We also 
probed whether the definition of elevated hsTnI using a gender-neutral or 
gender-specific cutoff influenced our results. In that analysis, 76.2% (618/811) of 
subjects had non-elevated hsTnI and 18% (146/811) had elevated hsTnI 
irrespective of the cutoff used. There were 30 subjects (all females) who had 
elevated hsTnI with the gender-specific cutoff only, and 17 subjects (all males) 
who had elevated hsTnI with the gender-neutral cutoff only. Patients with 




events than those with non-elevated hsTnI irrespective of the cutoff used (Hazard 
ratio: 3.53 [95% CI: 2.51 – 4.97]). Furthermore, subjects who had elevated hsTnI 
only with the gender-specific cutoff and those who had elevated hsTnI only with 
the gender-neutral cutoff, were at higher risk of adverse events than those with 
non-elevated hsTnI irrespective of the cutoff used (Hazard ratios 2.21 [95% CI: 
1.07 – 4.57] and 2.72 [95% CI: 1.18 – 6.23] respectively). 
Discussion 
This is the first report of hsTnI data using this newly approved highly sensitive 
assay in unselected ED subjects with possible ACS. Since this assay detects 
values in 96% of normal subjects,39 these data may represent a better evaluation 
of the effects of the most sensitive hsTn assays when used in the ED, than 
assays that detect fewer subjects. Thus, it provides new guidance concerning the 
use of this assay in unselected ED subjects with possible ACS. Our data indicate 
that hsTn assays will assist in diagnosing ACS earlier in some subjects but the 
number of such subjects will not increase markedly. The preponderance of novel 
elevations which in this series is roughly 10% will be observed mainly in subjects 
with non-ACS conditions. Although all of the clinical implications of these 
elevations are not yet clear, patients with these new elevations have a risk of 
death or admission for a cardiac condition that is similar to those who currently 
have cTnI elevation. This suggests that at minimum, these patients will need 
additional evaluation to determine the etiology of hsTnI elevation and close 
follow-up to properly manage underlining conditions that may result in future 




Most of those with elevations will have ADHF and other non ACS diagnoses such 
as volume overload from etiologies other than heart failure, cardiac (non-acs) 
conditions or cardiac conditions that complicate other primary diagnoses. The 
largest group (20% overall or 25% if the gender-specific cutoff is used) was 
ADHF.  The causal mechanisms for elevations of hsTn in ADHF may include: 
increased wall stress, epicardial coronary artery disease, endothelial dysfunction, 
oxidative stress, neurohormonal activation, altered calcium handling and 
inflammatory cytokines.96 It has also been suggested that elevated cTn may also 
be a mediator, leading to anti-cTn antibodies that result in worsening ADHF.97   
Thus, it is likely as in prior studies that hscTn elevations in subjects with ADHF 
will associated with increased short-term mortality and readmissions especially if 
the pattern of the values is rising.84,98,99  Most of our subjects and especially 
those who were discharged did not have rising values.  Larger future studies are 
necessary to determine if ADHF subjects with hsTnI elevations will benefit from 
more aggressive care.   
The prevalence of elevated hsTnI will depend in part on whether a gender-
specific or a single cutoff for the 99th % URL of the high sensitivity assay is used.  
We have argued for gender specific cutoffs because the 99th% URL for women 
with all hscTn assays is lower and because women have been reported to have 
lower hscTn values56  and have been reported to less often have elevated cTn 
with ACS.57  Our data further substantiate this important issue.  The reported 
under treatment of women with ACS may be related in part to this issue. The use 




a gender-neutral cutoff (91 [68 females] vs 75 [38 females]) including in subjects 
with ADHF.  Our data demonstrates that patients who only have elevated hsTnI 
with either the gender-neutral or the gender-specific cutoff , are at high risk for 
adverse event. Additional studies are needed to better understand the optimal 
cutoff for clinical use.  
It is also worth noting that 7 subjects had elevated cTnI with the standard assay 
but did not have elevations with the hsTnI assay.  The one marked elevation may 
have been due to heterophilic antibodies which can cause elevations.100 The 
other 6 reinforce the dictum that all cTn assays are different and one cannot 
extrapolate one to one from one assay to another.  
Limitations 
Our study has important limitations. First, our clinical chemistry laboratory only 
reported cTnI values of >60ng/L and not the 99th%. The use of the 99th% might 
have slightly reduced the prevalence of new positive hsTnI values.  However, as 
reported in our sensitivity analyses, it is likely that the principles we report will be 
similar if the 99th% was used.  Second, 6.5% (53/815) of enrolled subjects were 
lost to follow-up after their index discharge from the ED/hospital. They also did 
not have a death record in the Social Security Death Master file. It is unlikely that 
loss to follow up is associated with cTnI or hsTnI level, and thus it is unlikely to 
affect our conclusions. Third, in our cohort, only 58.4% of enrolled subjects had 
serial hsTnI measurements and 76.1% had serial cTnI.  Some subjects with one 
cTnI measurement had onset of symptoms>8 hours, others had CT coronary 




reasons. However, these data reflect a real world experience. Fourth, one could 
argue that the inclusion of subjects with shortness of breath biases the analysis.  
However, ED physicians feel an obligation to exclude ACS in certain subjects 
with shortness of breath since this symptom can be an angina equivalent.  Had 
this group not been included the frequency of hsTnI elevations would have been 
lower. It should also be noted that a rising pattern of values in this group with 
ADHF has recently associated with adverse events.101 Fifth, adjudication of final 
diagnoses was based on a current cTnI assay and all of the hospital records, 
potentially leading to an underestimation of AMI. However, for subjects with serial 
hsTnI samples, we re-analyzed the data for rising patterns in hsTnI using the 
ESC criteria. Finally, although the prevalence of ACS in this population was low, 
typical of an urban US ED population. Finally, although the frequency of ACS in 
reported in larger European studies is higher102 due to different screening 
procedures, many smaller centers are likely to have to evaluate a more 
heterogeneous group such as we do in our center and we only included subjects 
whose physicians ordered a cTnI level to exclude ACS.   
Conclusion 
The frequency of previously unrecognized hsTnI elevation is URL-dependent and 
ranges between 10.5% and 12.7%. Patients with previously unrecognized hsTnI 
elevation have a higher risk for adverse event than those with non-elevated cTnI 
and hsTnI. Additionally, they have a similar risk for adverse events as those who 





Table 2.1: Characteristics of enrolled subjects 
Characteristic Number (%) 
Median Age in years (IQR) 55.4 (48.3–64.7) 
Gender  
• Female  429 (52.6) 
• Male  386 (47.4) 
Ethnicity  
• Non-Hispanic Black  510 (62.6) 
• Non-Hispanic White  222 (27.2) 
• Hispanic    19 (2.3) 
• Asian    18 (2.2) 
• Native-American    43 (5.3) 
• Native-Hawaiian      3 (0.4) 
Insurance  
• Medicare  231 (28.3) 
• Medicaid  219 (26.9) 
• Commercial  270 (33.1) 
• HMO    24 (2.9) 
• VA    14 (1.7) 
• None    57 (7.0) 
Transportation  
• Self-transport  603 (74.0) 
• Ambulance  206 (25.3) 
• Transfer from other facility       6 (0.7) 
Education  
• Did not complete high school  224 (27.6) 
• Completed high school  251 (30.9) 
• Some college  178 (21.9) 
• Completed college    99 (12.2) 
• Completed graduate or professional school     60 (7.4) 
Currently employed  261 (32.1) 
Current cigarette smoker  291 (35.7) 
Current cocaine use     34 (4.2) 
Family history of AMI or sudden cardiac death  260 (31.9) 
History of hypertension  514 (63.1) 
History of diabetes  242 (29.7) 
History of high cholesterol  344 (42.2) 
History of AMI or revascularization   206 (25.3) 
History of congestive heart failure  173 (21.2) 
History of stroke  118 (14.5) 
Aspirin within last 7 days  559 (68.6) 
Plavix    93 (11.4) 
Nitroglycerin  110 (13.5) 
Lipid lowering agent  297 (36.4) 




Median mean arterial pressure (IQR) 97 (86.3 – 111.3) 
 
Table 2.2: Frequency of previously unrecognized cTnI elevation on initial 











All (n=717) 75 (10.5%) 91 (12.7%) 
Acute coronary syndrome (n=17)   3 (17.6%)   2 (11.8%) 
Acutely Decompensated Heart Failure (n=47) 15 (31.9%) 22 (46.8%) 
Volume overload, etiology unclear/non-cardiac 
(n=7) 
  3 (50.0%)   5 (83.3%) 
Pulmonary embolus (n=7)   0 (0%)   0 (0%) 
Cardiac, non-acute coronary syndromed (n=35)   4 (11.4%)   4 (11.4%) 
Others (n=605) 50 (8.3%) 58 (9.6%) 
a = Single cutoff=26.2 ng/L 
b = Gender specific cut-off: Males = 34.2 ng/L; Females = 15.6 ng/L 
d = Cardiac, non-acute coronary syndrome defined as Myocarditis, Pericarditis, 






Table 2.3: Frequency previously unrecognized hsTnI elevations on initial 
blood draw (based on chief complaint) 








All complaints (n=717) 75 (10.5%) 91 (12.7%) 
Chest pain (n=337) 34 (10.1%) 34 (10.1%) 
Shortness of breath (n=88) 13 (14.8%) 17 (19.3%) 
Cardiac-relatedc (n=82)   5 (6.1%) 11 (13.4%) 
Other (n=210) 23 (11.0%) 29 (13.8%) 
a = Single cutoff=26.2 ng/L 
b = Gender specific cut-off: Males = 34.2 ng/L; Females = 15.6 ng/L 
c = Cardiac-related symptoms defined as: Dizziness, Syncope, Lightheadedness, 
Palpitations, Rapid heart beat, Irregular heart beat, Cardiac pacemaker and 
Hypertension. 
 
Table 2.4: Sensitivity of results to changing definition of previously 
unrecognized cTnI elevation 
 Any elevated cTnI on 0, 3, 6 or 
9 hour sample instead of 
elevated cTnI on initial sample 
only 
Abbott cTnI instead of 
Beckman cTnI 
 n Hazard ratio (95% CI) n Hazard ratio 
- cTnI, - hsTnI 631 1.00 (Reference) 637 1.00 (Reference) 
+cTnI, - hsTnI   17 1.43 (0.45 – 4.53)    6 1.10 (0.15 – 7.91) 
- cTnI, +hsTnI   61 3.14 (1.99 – 4.94)  65 2.96 (1.89 – 4.62) 









o Declined consent, n=366
o No research blood sample, n=144
o Left against medical advice, n=6
o Repeat enrollment = 27
Included in final analysis, 
n=815
Non-elevated cTnI and hsTnI 
(n = 641)
•  Adverse events (n=85)
Elevated cTnI but non-
elevated hsTnI (n=7)
• Adverse events (n=1)
Non-elevated cTnI but 
elevated hsTnI (n=75)
• Adverse events (n=31)
Elevated cTnI and hsTnI 
(n=88)




Figure 2.2: hsTnI values at ED presentation among subjects with non-



























Figure 2.3: Occurrence of adverse events during the follow-up year 
 
  













Time from ED presentation (da
S(
t)
Beckman cTnI & Abbott hsTnI >99th%; n=88, events=32
Beckman cTnI>99th & Abbott hsTnI<99th; n=7, events=1
Beckman cTnI <99th% & Abbott hsTnI >99th%; n=75, events=31





Supplemental Table 2.1: Comparison of enrolled to subjects with a troponin 
order who presented during outside enrollment hours. 
Demographics Enrolled 
n = 815 
Outside enrollment 
hours 
n = 1724 
p-
value 
Age in years 55 (48 – 64)   54 (53 – 55) 0.19 
Gender   0.27 
• Male  429 (52.6)   867 (50.3)  
• Female  386 (47.4)   857 (49.7)  
Race   0.55 
• White 228 (28.0)   427 (24.8)  
• African-American 565 (69.4) 1242 (72.1)  
• Other   21 (2.6)     55 (3.1)  
Admitted to the hospital 393 (48.2)   890 (51.6) 0.11 
  
Supplemental Table 2.2: Adjudicated diagnoses according to cTnI 
(Beckman) and hsTnI values (Abbott) 












Acute coronary syndrome   14 (2.2) 0 (0) 23 (25.3)   3 (4.0) 
Acutely decompensated heart failure   32 (5.0) 1 (14.3) 14 (15.4) 15 (20.0) 
Volume overload unclear 
etiology/non-cardiac 
    3 (0.5) 0 (0)   2 (2.2)   3 (4.0) 
Pulmonary embolus     7 (1.1) 0 (0)   0 (0)   0 (0) 
Cardiac, non-ACS   31 (4.8) 0 (0)   6 (6.6)   4 (5.3) 







Supplemental Figure 2.1: Occurrence of adverse events during the year 
following ED/hospital discharge (previously undetected cTnI now defined 

















Time from ED presentation (da
S(
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Beckman cTnI & Abbott hsTnI >99th%; n=102, events=39
Beckman cTnI>99th & Abbott hsTnI<99th; n=17, events=3
Beckman cTnI <99th% & Abbott hsTnI >99th%; n=61, events=24




Supplemental Figure 2.2: Occurrence of adverse events during the year 
following ED/hospital discharge (previously undetected cTnI now based on 
Abbott cTnI not Beckman cTnI) 
 
  













Time from ED presentation (da
S(
t)
Abbott cTnI & Abbott hsTnI <99th%; n=637, events=84
Abbott cTnI<99th% & Abbott hsTnI >99th%; n=65, events=25
Abbott cTnI >99th%, Abbott hsTnI <99th%; n=6, events=1




Supplemental Figure 2.3: Occurrence of adverse events during the year 


















Time from ED presentation (da
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<99th% both gender-specific & gender-neutral; n=618, events=78
>99th% both gender-specific & gender-neutral; n=146, events=57
>99th% gender-specific only (all females); n=30, events=8




Supplemental Material: Criteria for Adjudication of a final diagnosis 
Patients will be assigned one of the following final diagnoses: 
a. Myocardial Infarction 
b. Unstable Angina 
c. Volume overload due to CHF 
d. Volume overload due to ESRD 
e. Volume overload due to CHF or ESRD 
f. Pulmonary Embolism 
g. Cardiac (non-ACS) 
h. Other 
Definitions  
Myocardial Infarction: Subjects with no recent revascularization, in whom 
cardiac troponin I was never elevated or have been documented to return to 
normal after a prior elevation, who meet at least one of the following criteria: 
1. Typical cardiac biomarker rise and/or fall (a second troponin value 
drawn within 3 to 6 hours after the initial positive troponin value is at 
least 30% higher or lower than the initial positive troponin value) 
AND at least one of the following: 
a. Ischemic discomfort at rest lasing ≥10 minutes 
b. ECG changes indicative of ischemia (ST elevation ≥0.1 mV or ST 
depression ≥0.05 mV, or new T-wave inversions. OR Development 
of new, abnormal Q waves (≥30 msec in duration and ≥1 mm in 




or increase R amplitude in V1-V3 consistent with posterior 
infarction. 
2. For patients with a baseline troponin elevation the appropriate delta 
criteria should be >20% and not 30% within 6 to 9 hours. Or at least a 
change of 0.02 ng/ml or more (30% of the 10% CV [0.06ng/ml]) 
3. Autopsy findings of an acute MI 
4. Sudden unexpected cardiac death, including cardiac arrest, often with 
symptoms suggestive of myocardial ischemia, accompanied by 
presumably new ST elevation, or new LBBB, or evidence of fresh 
thrombus in a coronary artery by angiography and/or at autopsy, but death 
occurring before blood samples could be obtained, or at a time before the 
appearance of cardiac biomarkers in the blood 
Unstable Angina:  
1. Does not meet definition for myocardial infarction and has one of the 
following characteristics.  
a. Chest pain or angina equivalent at rest or in accelerating pattern 
AND at least one of the following objective signs: 
i. Positive stress test (imaging or ECG consistent with 
ischemia 
ii. Cath ≥70% stenosis or thrombus  
iii. CTA coronary with > 70% stenosis  
iv. Patient has an acute myocardial infarction or sudden, 




b. History concerning for unstable angina as per inpatient 
documentation (has typical angina at rest or a deterioration of 
previously stable angina), however, optimal medical management 
pursued, instead of definitive testing and invasive management. 
Volume overload most likely due to Congestive Heart Failure (CHF) 
1. No ESRD 
2. Patient complains of dyspnea, OR orthopnea, OR edema AND at least 
one of the following: 
a. Inpatient note or ED note strongly suggestive of chf exacerbation. 
b. Pulmonary vascular congestion on chest radiography  
c. New or worsening LE edema 
d. Pro-BNP >1000 
Volume overload most likely due to End Stage Renal Disease (ESRD) 
1. Pulmonary congestion on CXR 
2. History of ESRD or GFR<30 mL/min/1.73m2  
And at least one of the following 
1. History of missed hemodialysis, , less than normal volume take off during 
previous HD 
2. CHF exacerbation not the most likely cause of volume overload 
Volume overload may be due to CHF or ESRD 
1. Pulmonary congestion on CXR 





1. As per CT PE protocol read or high probability of PE per VQ scan 
Cardiac (non-ACS):  
1. Persons in this category are those whose most whose presenting 
symptoms are most likely due to a cardiac (non-ACS) condition, such as: 
Myocarditis, Pericarditis, Valvular disorder, Arrhythmia 
Other: All others 
Ascertainment of Adverse cardiac events on follow-up 
Major Adverse Cardiovascular Events (MACE): Cardiovascular death, MI, 
unstable angina pectoris (UAP), coronary revascularization and/or re-
hospitalization that are distinct from the qualifying event (after patient’s initial ED 
presentation). 
Myocardial infarction: As above 
Unstable angina: As above 
Cardiovascular Death: Any sudden cardiac death, death due to acute 
myocardial infarction, death due to heart failure, death due to stroke, and 
death due to other cardiovascular causes. In addition, any death without a 
clear non-cardiovascular cause, or a death without known cause will be 
considered cardiovascular death. 
Urgent Revascularization: Coronary revascularization during an 
unscheduled visit to healthcare facility or during an unplanned (or 




Note: Attempted revascularization procedures, even if not successful will 
be counted. Potential ischemic events meeting the criteria for myocardial 
infarction will not be adjudicated as urgent coronary revascularization. 
Re-hospitalization: Coronary ischemia requiring re-hospitalization is 
defined as an event not meeting the definitions of myocardial infarction or 
urgent coronary revascularization and meeting the following criteria: 
• Ischemic discomfort lasting ≥10 minutes at rest, or repeated 
episodes at rest lasting ≥5 
• Prompting hospitalization (including overnight stay on an inpatient 
unit) within 48 hours of the most recent symptoms or prolonging 
hospitalization if occurring during existing hospitalization. 
AND at least one of the following additional criteria for coronary artery 
disease and/or ischemia: 
• New and/or dynamic ST-depression or ST-elevation  
• Definite evidence of ischemia on stress echocardiography, 
myocardial scintigraphy  
• Angiographic evidence of epicardial coronary stenosis of ≥70% 
Note: If subjects are admitted with suspected myocardial ischemia, and 
subsequent testing reveals non-cardiac or non-ischemic etiology, this will 
not be adjudicated as meeting this definition. Potential ischemic events 
meeting the criteria for myocardial infarction will not be adjudicated as 
ischemia requiring hospitalization. 




ECGs will be reviewed by an independent ECG review committee supervised by 
Larisa Tereshchenko M.D., Ph.D. 
• ST Elevation Myocardial Infarction (STEMI) 
o No LBBB or LVH 
o New ST elevation at the J-point in two contiguous leads with the 
cut-off points:  
 > 0.1 mV in all leads except leads V2 – V3 in men and 
women 
 In leads V2 – V3,  > 0.2 mV in men > 40 years and > 0.25 mV 
in men <40 years 
 In leads V2 – V3,  > 0.15 mV in women  
• ST elevation in aVR or V1 only 
o Does not meet STEMI criteria and ST > 0.1mV 
• Isolated Posterior Myocardial Infarction 
o Does not meet 2 criteria above 
o Isolated ST depression > 0.05 mV in V1 – V3 
• Significant ST depression and T-wave changes 
o Does not meet 3 criteria above 
o New horizontal or down-sloping ST depression > 0.05 mV in two 
contiguous leads; and/or T inversion > 0.1 mV in two contiguous 
leads with prominent R-wave or R/S ratio >1 (including 
pseudonormalization of T waves) 




o Does not meet any of 4 criteria above 
o ST elevation > 0.05mV in but does not meet STEMI criteria 
o T wave changes <0.1 mV or not in contiguous leads 
• Normal ECG 
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 Title and 
abstract 
1 (a) Indicate the study’s design with a 
commonly used term in the title or the 
abstract 
26 
(b) Provide in the abstract an informative 
and balanced summary of what was done 





2 Explain the scientific background and 
rationale for the investigation being 
reported 
28 




Study design 4 Present key elements of study design early 
in the paper 
28 
Setting 5 Describe the setting, locations, and 
relevant dates, including periods of 




Participants 6 (a) Give the eligibility criteria, and the 
sources and methods of selection of 
participants. Describe methods of follow-up 
29 
(b) For matched studies, give matching 
criteria and number of exposed and 
unexposed 
NA 
Variables 7 Clearly define all outcomes, exposures, 
predictors, potential confounders, and 






8*  For each variable of interest, give sources 
of data and details of methods of 
assessment (measurement). Describe 
comparability of assessment methods if 
there is more than one group 
29, 30, 
31 
Bias 9 Describe any efforts to address potential 






Study size 10 Explain how the study size was arrived at 32 
Quantitative 
variables 
11 Explain how quantitative variables were 
handled in the analyses. If applicable, 






12 (a) Describe all statistical methods, 




(b) Describe any methods used to examine 
subgroups and interactions 
31 and 
32 
(c) Explain how missing data were 
addressed 
31 
(d) If applicable, explain how loss to follow-
up was addressed 
31 
(e) Describe any sensitivity analyses 31 
Results  
Participants 13* (a) Report numbers of individuals at each 
stage of study—eg numbers potentially 
eligible, examined for eligibility, confirmed 
eligible, included in the study, completing 
follow-up, and analysed 
32 and 
42 
(b) Give reasons for non-participation at 
each stage 
42 
(c) Consider use of a flow diagram 42 
Descriptive 
data 
14* (a) Give characteristics of study 
participants (eg demographic, clinical, 




(b) Indicate number of participants with 
missing data for each variable of interest 
42 
(c) Summarise follow-up time (eg, average 
and total amount) 
35 
Outcome data 15* Report numbers of outcome events or 
summary measures over time 
35 and 
46  
Main results 16 (a) Give unadjusted estimates and, if 
applicable, confounder-adjusted estimates 
and their precision (eg, 95% confidence 






were adjusted for and why they were 
included 
(b) Report category boundaries when 
continuous variables were categorized 
30, 31 
(c) If relevant, consider translating 
estimates of relative risk into absolute risk 




17 Report other analyses done—eg analyses 








Limitations 19 Discuss limitations of the study, taking into 
account sources of potential bias or 
imprecision. Discuss both direction and 
magnitude of any potential bias 
35 
Interpretation 20 Give a cautious overall interpretation of 
results considering objectives, limitations, 
multiplicity of analyses, results from similar 





21 Discuss the generalisability (external 
validity) of the study results 
37 
Other information  
Funding 22 Give the source of funding and the role of 
the funders for the present study and, if 
applicable, for the original study on which 
the present article is based 
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*Give information separately for exposed and unexposed groups. 
 
Note: An Explanation and Elaboration article discusses each checklist item and 
gives methodological background and published examples of transparent 
reporting. The STROBE checklist is best used in conjunction with this article 
(freely available on the Web sites of PLoS Medicine at 
http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). 






Chapter 3: Independent predictors of high sensitivity troponin I values in patients 
evaluated for acute coronary syndrome who are determined to have a primary 
non-cardiac diagnosis. 
Korley FK, DeFilippis AP, Schulman SP, Sokoll LJ, Stolbach AI, Bayram JD, 
Omron R, Post WS, Fernandez, C, Jaffe AS. 
Abstract 
Objective: To investigate the factors associated with elevated high sensitivity 
troponin I (hsTnI) in emergency department (ED) patients with a primary non-
cardiac diagnosis. 
Methods: A cross-sectional study of patients in urban academic ED who were 
diagnosed with primary non-cardiac diagnosis was conducted. hsTnI was 
measured using the Abbott Laboratories’ (Abbott Park, IL) research-use 
ARCHITECT STAT high sensitive Troponin I assay. Patient diagnoses were 
adjudicated by a panel of ED physicians and cardiologists blinded to hsTnI.  
Results: Of 664 patients, 606 (91.3%) had detectable hsTnI and 96 (14.5%) had 
values >99th%.  Patients with hsTnI >99th percentile were more likely to have a 
prior history MI/revascularization, congestive heart failure, poor renal function, 
hypotension or tachycardia. Of the 341 (51.4%) patients in whom initial and 3 
hour hsTnI were measured, 8 (2.3%) had a significant change in hsTnI at 3 hours 
using criteria of the European Society of Cardiology. 
Conclusions: Using the Abbott assay, hsTnI will be detectable in >90% of ED 




hsTnI>99th%.  Prior history MI/revascularization, congestive heart failure, poor 
renal function, hypotension or tachycardia independently associated with 







High sensitivity troponin (hsTn) assays may be cleared by the Food and Drug 
Administration in the future, but are in use in other parts of the world.103 Clinical 
use of more sensitive assays and the guideline recommended cut off values will 
result in earlier diagnosis of myocardial infarction (MI),91 reclassification of a 
subset of patients currently diagnosed with unstable angina as non-ST elevation 
MI (NSTEMI), novel strategies for ruling out MI,28,91 and improved risk-
stratification of patients with other conditions that cause myocardial injury.84,85,104 
With hsTn assays, for the first time in clinical settings, clinicians will see 
measured hsTn values in most healthy individuals15 and in many emergency 
department (ED) patients who have cardiovascular comorbidities. For example, 
prior studies have demonstrated that older age, male gender, higher systolic 
blood pressure, higher left ventricular mass and reduced renal function are each 
independently associated with higher hsTn values.105,106 Accordingly, the 
diagnosis of AMI will require a changing pattern of values.107   
Importance 
To our knowledge, prior studies have not examined how these factors contribute 
to elevated high sensitivity troponin I (hsTnI) among undifferentiated US ED 
patients evaluated for acute coronary syndrome (ACS) have a primary non-
cardiac diagnosis.  




The goal of this study was to investigate the independent predictors of hsTnI in a 
subset of ED patients in whom a primary non-cardiac diagnosis was made.   
Methods 
Study design and setting 
We conducted a prospective observational study of patients evaluated for ACS, 
who were diagnosed with a non-cardiac condition by adjudication committee of 
board certified clinicians. This study was nested in an ongoing prospective cohort 
study of ED patients evaluated for ACS (Korley et al, In press). The study was 
conducted at an urban academic ED seeing 65,000 patients a year, and was 
approved by our institutional review board.  
Selection of Participants  
Patients included in this cohort study had a recorded chief complaint of chest 
pain or shortness of breath, a non-diagnostic ECG and cardiac troponin I (cTnI) 
ordered by the treating clinician. Additionally, all patients with other chief 
complaints who had cTnI testing were considered eligible if their treating clinician 
confirmed when asked that ACS was a possible diagnosis. Eligible patients 
provided written informed consent. Continuous enrollment of consecutive 
patients occurred on weekdays from 9:00 am till 9:00 pm. Patients with the 
following were excluded: ST elevation myocardial infarction (STEMI), left against 
medical advice, initial research blood sample was missed or could not be 
obtained.  




Demographic and clinical information was collected by trained research 
assistants, and entered directly into an electronic database via an online data 
collection tool REDCAP.92 The first documented blood pressure, heart rate and 
glomerular filtration rate were electronically extracted from patient charts. Each 
time blood samples were drawn for clinical cTnI testing, an additional 5 mL of 
blood was collected, centrifuged, and serum aliquoted and stored in a -80°F 
freezer. Sample storage occurred within 2 hours of blood draw. For clinical 
decision making, the hospital cTnI assay was the Beckman Coulter (Chaska, 
MN) Access II AccuTnI assay.  The 99th% upper reference limit (URL) for this 
assay is 40 ng/L.  The co-efficient of variation (CV) for this assay is 14% at 40 
ng/L: the 10% CV value is 60 ng/L. Our clinical laboratory only reports values of 
cTnI > 60 ng/L (the decision making cut-off for the institution). hsTnI values were 
measured in batches, at least one month after initial presentation, using the 
Abbott Laboratories’ (Abbott Park, IL) research-use ARCHITECT STAT high 
sensitive Troponin I assay. The 99th % (upper reference limit) for this assay is 
34.2 ng/L for males, 15.6 ng/L for females and 26.2 ng/L overall.  The limit of 
detection (LOD) for this assay is 1.2 ng/L.93 hsTnI data were not available to 
clinicians for medical decision making.  
Estimated glomerular filtration rate (GFR) was calculated using an enzymatic 
serum creatinine result (Roche Modular and Cobas c701, Roche Diagnostics, 
Indianapolis, IN) and the IDMS-traceable 4-variable Modification of Diet in Renal 




Clinical diagnoses were adjudicated by a committee comprised of four board 
certified emergency physicians and two board certified cardiologists. Two 
members blinded to high sensitivity troponin data, reviewed the medical records 
and assigned one of the following diagnoses: AMI, unstable angina, acutely 
decompensated heart failure (ADHF), volume overload from other causes, 
cardiac (non-ACS), pulmonary embolism, and other. If there was disagreement 
between committee members, a third committee member arbitrated.  AMI was 
defined according to the universal definition of AMI, except for the cTnI cutoff 
imposed at our institution.49 A significant rising and/or falling pattern in cTnI was 
defined as a change of at least 30% at the 10% co-efficient of variation level (18 
ng/L or greater within 6-9 hours).63 Unstable angina was defined based on the 
clinical history, objective ECG findings, a positive stress test or coronary artery 
stenosis on CT coronary angiography or coronary angiography catheterization of 
70% or greater.  Acutely decompensated heart failure (ADHF) was defined using 
a modified Framingham criteria.94 Patients with radiographic or clinical evidence 
of volume overload suspected from non-cardiac conditions such as end-stage 
renal disease were classified as volume overload and not ADHF. Patients 
diagnosed with myocarditis, or pericarditis, or valvular disorders or arrhythmia 
were classified as: cardiac (non-ACS).  A board certified cardiologist also 
reviewed all subjects diagnosed with AMI or unstable angina to confirm 
diagnoses. This report includes only patients diagnosed as “Other”.  




Our primary outcome was hsTnI analyzed both as a continuous variable and as a 
categorical variable (>99th% or <=99th%). Gender-specific cut off values were 
also probed. We also examined variations in hsTnI according to the primary 
diagnosis assigned by treating ED clinicians. 
Analysis        
Demographic and clinical characteristics of the study population have been 
summarized using descriptive statistics. Differences in demographic and clinical 
characteristics between patients with hsTnI>99th% and those with hsTnI<=99th% 
were examined using Student’s t-tests for continuous variables (they all 
approximated a normal distribution) and χ2 for categorical variables. To identify 
independent predictors of hsTnI and hsTnI >99th%, we used univariable and 
multivariable linear regression and logistic regression models. Blood pressure 
was categorized as hypotension (systolic <90 mmHg or diastolic <60 mmHg), 
severely elevated (systolic >180 mmHg or diastolic >120 mmHg) or neither, 
based on generally accepted definitions,108,109 and a review of Lowess smoothing 
plots that examined the association between blood pressure and hsTnI. Similarly, 
heart rate was dichotomized into heart rate> or <110 beats per minute (bpm) 
based on biological plausibility and a review of lowess plots. Variables included 
in the final multivariable linear and logistic regression models (age; prior history 
of hypertension, diabetes, MI/revascularization, CHF; renal function measured by 
GFR; family history of M/sudden death; blood pressure; heart rate) were selected 
based on apriori literature review. Additionally, the final multivariable models 




approximated statistical significance (p<0.2). We measured collinearity among 
the variables included in the final models using the variance inflation factor (VIF). 
None of the included variables met our predetermined criterion for severe 
collinearity (VIF>10). Since hsTnI values are not normally distributed, they were 
natural log transformed prior to including them in the linear regression models.  
The proportion of variability in hsTnI that can be explained by variables included 
in the multivariable linear regression model was estimated with the co-efficient of 
determination (R2). All statistical analyses were performed using STATA/MP 
statistical software version 11.2 (StataCorp, College Station, Texas), and 
RStudio statistical software version 0.97.312. A two-tailed p-value of <0.05 was 
considered statistically significant. 
Results 
Independent determinants of hsTnI 
Between January 2012 and July 2012, 815 subjects were enrolled in the original 
cohort. This study focusses on 664 subjects within that cohort who were 
assigned a non-cardiac diagnosis by an adjudication committee (Figure 3.1). 
Demographic and clinical characteristics of the study population are presented in 
Table 3.1. hsTnI values were detectable in 91.3% (606/664) of the study 
population and 14.5% (96/664) had values> 99th%. Distribution of hsTnI values in 
the study population is presented in Figure 3.2. Additionally, the distribution of 
hsTnI according to the primary diagnosis assigned by treating ED clinicians is 
presented in Figure 3.3. Patients with hsTnI>99th% were more likely to be older, 




a history of hypertension, or diabetes, or congestive heart failure, or prior 
MI/revascularization, or reduced renal function or an elevated heart rate at ED 
presentation. However, they did not have an increased likelihood of presenting 
with chest pain or shortness of breath (Table 3.1). However, after adjusting for 
confounders, only reduced renal function, hypotension and heart rate >110 bpm 
were found to be independent predictors of hsTnI>99th% (Table 3.2). The 
variables included in the final multivariable linear regression model (Table 3.3) 
explained 31% of the variability in hsTnI values. Of all the variables investigated, 
the strongest predictor of hsTnI was reduced renal function (Figure 3.4).  
Three-hour hsTnI samples were available for 51.4% (341/664) of the study 
population and for 59.4% (57/96) of those with an initial hsTnI>99th%.  Of those 
with an initial hsTnI>99th%, 12.3% (7/57) had a 20% or greater change in hsTnI 
(criterion for significant change in hsTnI proposed by the European Society of 
Cardiology [ESC]95) in 3 hours. Similarly, of those with an initial hsTnI <= the 
99th%, 0.4% (1/284) had a change of at least 50% of the 99th percentile i.e. 13.1 
ng/L (ESC criterion95). 
Effect of the definition of 99th% on the prevalence of elevated hsTnI 
Assay manufacturers recommend using either a gender-neutral cutoff for the 
99th% of all patients (26.2 ng/L) or gender-specific cut-offs (male: 34.2 ng/L, 
female: 15.6 ng/L). If a gender-specific cut-off is used, the number of elevated 
hsTnI (>99th%) would increase from 96 (14.6%; 52 males and 44 females) to 104 
(15.7%; 41 males and 63 females). 85 patients had elevated hsTnI regardless of 





Our data provide important new information for clinicians regarding the 
determinants of hsTnI among ED patients evaluated for ACS who are in whom a 
primary non-cardiac diagnosis was made.  They demonstrate that when these 
assays are used, values will be measureable in 91% of patients with possible 
ACS in whom a primary non-cardiac diagnosis is made. Importantly, 14.5% of 
these patients will have hsTnI values greater than the 99th%. However, and a key 
to this analysis, very few (8 out of the 341 with serial samples) will have a rising 
pattern indicative of an acute event.  This will further amplify the tension that has 
existed for some time concerning how ED physicians should response to 
elevated cTn values.  Importantly, the use of gender specific cut off values will 
markedly reduce the frequency of elevations in men and markedly increase the 
frequency of elevations in women which may have a profound impact on the 
ability to properly refer such patients for subsequent appropriate care. 
Because cTn is released into circulation after damage to cardiac myocytes, their 
near perfect specificity for myocardial injury has allowed for fairly straightforward 
clinical decision making in evaluating patients in the ED.  If AMI was suspected, 
an elevated value was considered diagnostic in high risk patients and these 
individuals were admitted.  Even in the absence of AMI, elevations of cTn 
indicative of cardiac injury in critically ill patients have been documented to be 
associated with increased risk for mortality in multiple settings, including the 




although this approach itself has been controversial and results in excessive 
testing and utilization of resources.112  
With less sensitive assays, only higher values of troponin were detected and 
these values were associated with more severe cardiac injury and thus whether 
due to AMI or other cardiac abnormalities, such elevations were considered likely 
to be of clinical significance.  With the increasing sensitivity of cTn assays, 
including many more sensitive assays currently in use in the U.S.,  which detect 
chronic structural abnormalities45,105 well as acute events, this approach has 
become more and more problematic.  This will be further accentuated with hsTn 
assays.  Our data are reassuring however, that such patients will very 
infrequently have a changing pattern of values. 
Our results are similar to many others. A recent study that used the Siemens 
hsTnI assay, reported measurable hsTnI values in 93% of a cohort of healthy 
community residents.105  These data have been recapitulated with the Singulex 
hsTnI assay as well.113 Although, numerous studies have demonstrated the 
dose-dependent association between hsTn values and long term adverse cardiac 
events,45,46,113 it is unclear that such individuals are at increased short term risk, 
assuming they are clinically stable. Thus, an elevated hsTn value may not be 
sufficient to determine whether patients have an acute cardiac pathology.  Serial 
sampling of hsTn to determine whether a rising pattern exists will be the key to 
distinguishing between acute and non-acutely elevated hsTnI.58,62  In our cohort, 




Similar to prior studies114, reduced renal function was highly associated with 
increased hsTnI.  The reason for this is that renal disease and cardiac disease 
are frequently associated.115,116 Potential contributors to elevations in hsTnI 
among patients with reduced renal function include an increased prevalence of 
multivessel coronary artery disease117, volume overload with or without cardiac 
failure118 left ventricular hypertrophy in this population,119 and perhaps even the 
abnormal metabolic profile that exists in such patients.120 Regardless of the 
etiology, in our multivariable linear regression model that identified independent 
predictors of hsTnI (Table 3.3), after adjustment for history of heart failure and 
history of prior MI, CABG and prior coronary stents, the influence of reduced 
renal function persisted. One explanation that has been advanced has to do with 
the clearance of cTn.  More than 95% of the troponin I in human blood occurs as 
a binary troponin I and troponin C complex15, a relatively large molecule 
(approximately 42KDa, albumin is 66 KDa) , making it less likely to be cleared by 
the kidney. It is possible but unproven that smaller molecular weight degradation 
products of troponin I121 might be cleared by the renal system. Alternatively, 
cleavages of the protein may differ leading to reduced degradation.122 Thus serial 
measurement of hsTnI will be especially important in patients with reduced renal 
function. Current ESC guidelines recommend that for patients with an elevated 
baseline hsTnI a change of >20% within 3 or 6 hours constitutes a significant 
change.95 
Our data reveal that elevated blood pressure and elevated heart rate are both 




that the relationship between blood pressure and the risk of cardiovascular 
events is continuous and consistent, and independent of other risk factors.123  
However, many questions regarding the association between blood pressure and 
myocardial injury remain unanswered.  Perhaps with the use of hsTnI, new 
understandings will be possible to more accurately define both risk and the 
mechanisms responsible for it. 
A number of studies have reported significant differences in the 99th % value of 
hsTnI among males and females.39,105,124 Our data demonstrates that the use of 
a gender-specific cut-off will increase the prevalence of elevated hsTnI.  The 
majority of those with elevated hsTnI were females. Although data concerning 
these findings are unclear, it is likely that these elevations as with most others 
detected with hsTn assays define a group at enhanced risk.93,125  If so, adhering 
to this approach will improve the care of female patients significantly and avoid 
over testing in their male counterparts.  Additional studies are clearly needed to 
determine the proper approaches to these provocative findings.    
Limitations 
Based on our multivariable linear regression model (Table 3.3), the variables 
included in the model accounted for only 31% of the variability in hsTnI. This 
finding may reflect in part the fact that at least one known important predictor: left 
ventricular mass, was not included in our model.  We unfortunately did not have 
imaging on all these patients which might be helpful in defining the presence of 




targeting appropriate follow up for these individuals given the known prognostic 
value of these elevations.45,113  
Two other limitations are also clear.  First, it is essential that it be confirmed that 
our assumption that these patients are not at increased short term risk is correct.  
The fact that the primary diagnosis in these patients was non cardiac does not 
suggest that they do not have cardiac disease marked by the elevated hsTn 
value.  We are currently completing follow-up studies on this cohort to determine 
answer this critical question.  A second important limitation is that the diagnoses 
made in these patients were made not with the hsTnI but with a solid 
contemporary assay.  Indeed, the assay we used detects more normal subjects 
than others and thus is likely somewhat more sensitive than others39 despite the 
use of the 10% CV value and not the 99th% URL value.  Thus, many of the 
individuals who might have had a rising pattern of values may have been 
detected with the assay in use locally causing an underestimation of the 
frequency of this finding in our cohort.  Such concern reinforces the suggestion of 
the importance of choosing the proper standards for evaluating hsTn assays.107 
Conclusions 
With the use of the Abbott hsTnI assay, more than 90% of ED patients in whom a 
primary non-cardiac diagnosis is made will have detectable troponin I values. 
Prior history MI/revascularization, congestive heart failure, poor renal function, 














o Acute coronary syndrome, 
n = 40
o Acutely decompensated heart 
failure, n = 62
o Volume overload, etiology 
unclear, n = 8




Table 3.1: Demographic and Clinical Characteristics of Study Population 
 hsTnI <= 99th 
percentile 
n = 568 
hsTnI > 99th 
percentile 
n = 96 
P value 
Mean age in years (95% CI) 54.7 (53.6 – 
55.8) 
59.8 (56.8 – 62.7) <0.01 
Gender (%)     0.11 
• Male 258 (45.4) 52 (54.2)  
• Female 310 (54.6) 44 (45.8)  
Race (%)     0.64 
• Non-hispanic Black 359 (63.2) 60 (62.5)  
• Non-hispanic White 154 (27.1) 23 (24.0)  
• Hispanic   14 (2.5)   4 (4.2)  
• Other   41 (7.2)   9 (9.4)  
Insurance (%)     0.07 
• Medicare 138 (24.3) 34 (35.4)  
• Medicaid 167 (29.4) 22 (22.9)  
• Other 225 (39.6) 31 (32.3)  
• None   38 (6.7)   9 (9.4)  
Ambulance transport (%) 132 (23.2) 26 (27.1)   0.66 
History of Hypertension (%) 331 (58.3) 70 (72.9) <0.01 
History of Diabetes (%) 140 (24.6) 36 (37.5) <0.01 
Prior MI or revascularization 
(%) 
112 (19.7) 41 (42.7) <0.01 
History of CHF(%)   70 (12.3) 36 (37.5) <0.01 
History of high cholesterol (%) 218 (38.4) 39 (40.6)   0.68 
Glomerular filtration rate  
(per mL/min/1.73m2) 
  <0.01 
• >60 470 (82.8) 41 (42.7)  
• 30-60   83 (14.6) 33 (34.4)  
• <30   15 (2.6) 22 (22.9)  
Current cigarette smoker (%) 352 (62.0) 63 (65.6)   0.49 
Family history of heart attack or 
sudden death (%) 
174 (30.6) 37 (38.5)   0.12 
Blood pressure   <0.01 
• Hypotension   32 (5.6)   16 (16.7)  
• Severely elevated   59 (10.4)   18 (18.8)  
• Neither 477 (84.0)   62 (64.6)  
Heart Rate >110 bpm   56 (9.9)   18 (18.8)   0.01 
Probability that patient has non-
cardiac cause of symptoms 
(determined by treating 
clinician) 
    0.02 




• Medium 204 (37.0)   31 (33.0)  
• High 263 (47.7)   38 (40.4)  
Had chest pain or shortness of 
breath 
451 (79.4)   79 (82.3) 0.51 
 
Table 3.2: Factors associated with elevated hsTnI (>99th%) 
   Unadjusted Odds   Adjusted Odds 
Age per 10 year increase    1.33 (1.13 – 1.56)   1.10 (0.90 – 1.33) 
History of Hypertension    1.93 (1.19 – 3.11)   0.83 (0.46 – 1.50) 
History of Diabetes    1.83 (1.16 – 2.89)   1.03 (0.59 – 1.81) 
Prior MI or revascularization    3.04 (1.93 – 4.78)   2.07 (1.18 – 3.63) 
History of CHF   4.27 (2.63 – 6.92)   2.24 (1.24 – 4.06) 
Glomerular filtration rate  
(per mL/min/1.73m2) 
  
• >60   Reference (1.0)   Reference (1.0) 
• 30-60   4.56 (2.72 – 7.62)   3.59 (1.97 – 6.53) 
• <30 16.81 (8.10 – 34.88) 11.34 (4.99 – 25.77) 
Family history of heart attack or 
sudden death  
  1.42 (0.91 – 2.22)   1.28 (0.76 – 2.18) 
Blood pressure   
• Hypotension 3.85 (2.00 – 7.41) 2.56 (1.17 – 5.59) 
• Severely elevated 2.35 (1.30 – 4.24) 1.92 (0.96 – 3.91) 
• Neither Reference (1.0) Reference (1.0) 
Heart Rate >110 beats per 
minute 






Table 3.3: Multivariable model to determine independent predictors of 
hsTnI  
 % change in hsTnI (95% CI) 
Age per 10 year increase    18.0 (9.8 – 26.8) 
Gender (Reference is female)   42.2 (19.6 – 69.1) 
History of Hypertension    40.9 (15.5 – 71.8) 
History of Diabetes    19.2 (-3.4 – 47.2) 
History of High Cholesterol  -13.4 (-28.7 – 5.1) 
Prior MI or revascularization    25.3 (0.41 – 56.4) 
History of CHF   63.4 (26.5 – 111.1) 
Glomerular filtration rate  
(per mL/min/1.73m2) 
 
• >60 (Reference)  
• 30-60   62.3 (26.9 – 107.5) 
• <30 303.6 (173.3 – 496.0) 
Blood pressure  
• Hypotension   53.9 (9.7 – 115.8) 
• Severely elevated   51.1 (14.7 – 98.8) 
• Neither (Reference)  




































































Chapter 4: Rapidly Excluding Significant Coronary Artery Stenosis Using 
High Sensitivity Troponin I 
Korley FK, George RT, Jaffe AS, Saheed MO, Fernandez, C, Gerstenblith G, 
Berkowitz S, Hill PM 
Oral presentation at the 2013 annual meeting of the Society of Academic 
Emergency Medicine (SAEM) in Atlanta, Georgia. 
Background 
Indiscriminate use of CT coronary angiography (CCTA) in evaluating emergency 
department (ED) patients for suspected acute coronary syndrome (ACS) may 
unnecessarily expose them to financial harm, ionizing radiation and the risks of 
IV contrast dye. High sensitivity troponin I (hsTnI) improves the risk stratification 
of ED patients with suspected ACS. We determined whether hsTnI can identify 
patients with non-significant coronary artery stenosis (<50%) on CCTA.  
Methods 
We conducted a cross-sectional study in which we measured hsTnI in ED 
patients who received a CCTA as part of their evaluation for suspected ACS. 
hsTnI was measured using the Abbott Laboratories’ (Abbott Park, IL) research-
use ARCHITECT STAT high sensitive Troponin I assay.   
Results 
Of the 206 patients studied, 51.5% (106/206) had coronary arteries without 
plaque or lumen narrowing,  39.3% (81/206) had maximal coronary artery 




of 50-70% stenosis, and 2.9% (6/206) had at least one coronary artery with 
>70% stenosis. Median hsTnI values were higher among patients with maximal 
coronary artery stenosis of 50% or greater (median 6.4 [IQR: 5.1 – 11.2] ng/L) 
than in patients with maximal coronary artery stenosis <50% (median 3.1 [IQR: 
1.5 – 5.3]), p<0.01. Avoiding CCTA in patients with hsTnI <=1.2 ng/L will result in 
avoiding 20.3% (38/187) of the CCTAs with <50% stenosis, without missing any 
patients with significant stenosis. 
Conclusion:  
hsTnI measured with the Abbott assay can identify CCTA candidates with low 






Diagnostic evaluation of Emergency Department (ED) patients suspected of 
having acute coronary syndrome (ACS) remains time consuming and costly.126 In 
patients with ECG or biochemical evidence of myocardial infarction the diagnosis 
of ACS is fairly straight-forward.9 However, those without these findings undergo 
either functional testing to evaluate for provocable ischemia or anatomic imaging 
to evaluate for flow-limiting coronary artery stenosis.127 Coronary CT angiography 
(CCTA) visualizes coronary artery stenosis with excellent precision.128,129 It can 
be used to safely expedite the discharge of low risk ACS patients.130,131 However, 
as with all diagnostic tests, indiscriminate use of CCTA in a low to no risk 
population results in a decrease in its positive predictive value.132 Additionally, 
CCTA use is associated with financial costs, and radiation and contrast dye 
exposure. Thus careful selection of candidates for CCTA is of utmost importance. 
However, the literature on appropriate identification of candidates for CCTA is 
scant.  
High sensitivity troponin (hsTn) assays are able to measure up to 10 fold lower 
concentrations of troponin compared to contemporary assays. Prior studies using 
the high sensitivity troponin T (hsTnT) assay described an association between 
hsTnT and coronary artery disease (CAD) severity, and calcified and non-
calcified plaque burden, resulting in a high diagnostic accuracy for the 
differentiation of patients by plaque composition.133,134 To our knowledge no 
studies have investigated the association between high sensitivity troponin I 




known whether CCTA candidates who are unlikely to have significant coronary 
artery stenosis on CCTA (avoidable CCTA) can be identified using hsTnI. We 
hypothesized that median hsTnI values will be higher in patients with significant 
coronary artery stenosis than in those without. Additionally, we explored whether 
hsTnI as a screening test for CCTA candidates, can decrease the proportion of 
avoidable CCTAs (CCTAs with <50% stenosis) by 20% or greater, without 
missing patients with significant stenosis. 
Methods 
Study design and setting 
We conducted a cross-sectional study of ED patients who received a CCTA as 
part of their diagnostic evaluation for ACS. This study was nested in an 
institutional review board approved prospective cohort of ED patients evaluated 
for ACS at an urban academic ED (HopACS). The details of the characteristics of 
this cohort have been previously published (Korley et al, Heart 2013 in press).  
Selection of Participants 
Patients included in the original cohort were 18 years or older ED patients who 
had a recorded chief complaint of chest pain or shortness of breath and a non-
diagnostic ECG and cardiac troponin testing I (cTnI). Additionally, patients with 
other chief complaints who had cTnI testing were considered eligible if their 
treating physician confirmed when asked that ACS was a possible diagnosis. 
Enrollment of patients occurred on weekdays from 9:00 am till 9:00 pm. Patients 




(STEMI), left against medical advice, or if the initial research blood sample was 
missed or could not be obtained. Within this cohort, patients with no known 
history of coronary artery disease, who had a cTnI <60 ng/L using the Beckman 
Coulter (Chaska, MN) Access II AccuTnI assay (the clinical assay), and no 
contraindication to receiving a CCTA (recent CCTA, IV contrast dye allergy, renal 
insufficiency, beta-blocker intolerance, persistent tachycardia, non-sinus rhythm, 
inadequate IV access) received a CCTA at the discretion of treating emergency 
physicians and mid-level providers. Eligible patients provided written informed 
consent. 
Methods and measurements 
Trained research assistants interviewed consented subjects and their clinicians, 
collected demographic and clinical information, and entered this information 
directly into an electronic database via an online data collection tool REDCAP 92. 
Blood samples for hsTnI testing were drawn within 1-2 hours of ED presentation 
and prior to obtaining the CCTA.  Samples were centrifuged and serum aliquoted 
and stored in a -80°F freezer. Sample storage occurred within 2 hours of blood 
draw. hsTnI values were measured in batches, at least one month after initial 
presentation, using the Abbott Laboratories’ (Abbott Park, IL) research-use 
ARCHITECT STAT high sensitive Troponin I assay. The 99th % (upper reference 
limit) for this assay is 34.2 ng/L for males, 15.6 ng/L for females and 26.2 ng/L 
overall.  The limit of detection (LOD) for this assay is 1.2 ng/L 93. hsTnI data were 
used for research purposes only and not for clinical decision making.  




CCTA was performed using one of the following multidetector computed 
tomography scanning systems:  first generation dual-source CT (Somatom 
Definition, Siemens), second generation dual-source CT (Somatom Definition 
Flash, Siemens), and a 320-row detector CT scanner (Aquillion ONE, Toshiba).  
Following scout images, a non-contrast image was obtained and a coronary 
calcium score was calculated using the Agatston method.  CCTA was then 
acquired during the infusion of iodinated contrast at a rate of 4-6 ml/sec for a total 
of 50-100 ml.  CCTA was performed with prospective ECG-triggering, when 
applicable, to maintain a low radiation dose.   
CCTAs were read by board certified radiologists and cardiologists for clinical 
decision making. An emergency physician reviewed these clinical reads and 
categorized them into no stenosis (zero calcium score as calculated by the 
agatston method and no stenosis in any of the coronary arteries), 1-50% 
stenosis, 50 – 70% stenosis and stenosis of 70% or greater. Additionally, CCTA 
results were dichotomized into two categories: significant stenosis (50% or 
greater) and non-significant stenosis (less than 50% stenosis). 
Outcomes 
Our primary outcome was significant coronary artery stenosis. This was defined 
as coronary artery stenosis of 50% or greater in any coronary artery.  
Statistical Analysis  
Descriptive statistics were used to summarize study data. Continuous variables 




distributed, and with medians and corresponding interquartile ranges (IQR) if not 
normally distributed. Categorical variables were summarized as proportions. 
Differences between proportions were assessed with a χ2 test. The differences in 
median hsTnI levels between patients with significant stenosis and those without, 
was tested using the Wilcoxon rank-sum (Mann-Whitney) test. We examined the 
association between hsTnI and coronary artery calcium score using a linear 
regression model, with log-transformed hsTnI as the dependent variable. A two-
tailed p-value of <0.05 was considered statistically significant. All statistical 
analyses were performed using STATA/MP statistical software version 11.2 
(StataCorp, College Station, Texas), and RStudio statistical software version 
0.97.312. 
Results 
Our study population comprised of 206 patients who received a CCTA. Of this 
population there were 114 females (55.3%) and 92 males (44.7%). The median 
age was 50.9 years (IQR: 45.3 – 57.6). Detailed description of the demographics 
of the study population is provided in Table 4.1. About half of study patients had 
coronary arteries without plaque or lumen narrowing (51.5% [106/206]), 39.3% 
(81/206) had maximal coronary artery stenosis of less than 50%, 6.3% (13/206) 
had maximal coronary artery stenosis of 50-70% stenosis, and 2.9% (6/206) had 
at least one coronary artery with >70% stenosis. hsTnI was detectable in 81.6% 
(168/206) of the study population, and 2.4% (5/206) had hsTnI > the 99th% of a 
reference population of healthy adults. Median hsTnI values were higher among 




[IQR: 5.1 – 11.2] ng/L) than in patients with maximal coronary artery stenosis 
<50% (median 3.1 [IQR: 1.5 – 5.3]), p<0.01 (Figure 4.1).  hsTnI values were 
higher with increasing severity of coronary artery stenosis (Figure 4.2).  hsTnI 
discriminates between significant coronary artery stenosis (>=50%) and no 
significant coronary artery stenosis (<50%) with an area under the receiver 
operator curve (AUC) of 0.82 (95% CI: 0.74 – 0.89). Using ROC curve analysis, 
we determined that the optimal cut-off for discriminating significant stenosis 
(>=50%) is 3.2 ng/L. Avoiding CCTA in patients with hsTnI <=3.2 ng/L will result 
in avoiding 52.4% (98/187) of the CCTAs with <50% stenosis, without missing 
any patients with significant stenosis (Table 4.2). Similarly, avoiding CCTAs in 
patients with hsTnI at or below the limit of detection (LOD) will result in avoiding 
28.3% (38/187) of CCTAs with <50% stenosis, without missing any patients with 
significant stenosis.  
Discussion 
Our study demonstrates that hsTnI are higher in patients with significant coronary 
artery stenosis (>50%) than in those without. Additionally, we found that by using 
a cut-off of either hsTnI<LOD or hsTnI<3.2 ng/L we can avoid CCTAs in 20 – 
50% of patients who have no significant coronary artery stenosis. This finding 
has major implications for rapidly excluding significant coronary artery stenosis 
and ACS in a subset of ED patients. The idea of using undetectable or extremely 
low values of high sensitivity troponin to rapidly exclude AMI has been suggested 




study extends this idea by demonstrating hsTnI can be used to rapidly exclude 
significant coronary artery stenosis at ED presentation.  
Our finding of higher hsTnI in patients with significant coronary artery stenosis is 
consistent with work done by prior authors. Korosoglou et al in a study of 124 
patients with stable angina, described a strong correlation between hsTnT and 
total non-calcified plaque burden (r=0.79, p<0.001); and higher hsTnT values 
among patients with remodeled non-calcified plaque.133 Similar findings using 
with the hsTnT assay were also reported by Januzzi et al.136 It has also been 
established that hsTnT independently predicts 90-day adverse cardiac events 
after adjusting for cardiovascular risk profiling, calcium score and CCTA 
results.137  
Our findings are well grounded in biological plausibility. Spontaneous coronary 
microembolization occurs in vessel with atherosclerotic plaques.138 Additionally, 
subclinical episodes of plaque disruption and healing stimulate plaque growth 
resulting in high grade coronary stenosis.139 Until the recent introduction of high 
sensitivity troponin assays, detection of micoinfarctions occurring secondary to 
coronary microembolization was achieved mainly by advanced magnetic 
resonance imaging (MRI) techniques140 and the use of less sensitive biomarkers. 
Our findings of elevated hsTnI in patients with significant coronary artery stenosis 
suggest that coronary microembolization and microinfarction occurs with higher 
frequency in this group than in those without significant coronary artery stenosis.  
The limit of quantitation of the hsTnI assay used in this study is 6.0 ng/L. Given 




limit of detection, the use of cut-off values between the LOD and the LOQ will be 
ill-advised.141 For example, with the study assay a hsTnI value of 3.2 ng/L may 
not necessarily be different from a value of 5 ngL. Therefore, although according 
to our data, the use of 3.2 ng/L as the optimal cut-off for discriminating significant 
coronary artery stenosis results in avoiding about half of the CCTAs with no 
significant stenosis, it may also result in a misdiagnosis in patients with 
significant coronary artery stenosis. Therefore we recommend using the LOD as 
the optimal cut-off for discriminating significant coronary artery stenosis. 
Limitations 
Our study has two important limitations. First, our sample size is small. To be 
able to definitely state that patients with hsTnI<LOD have less than 1% chance of 
having significant coronary artery stenosis (the acceptable risk of major adverse 
cardiac events in chest pain patients discharged from the emergency 
department142), we need to study at least 370 patients with hsTnI<LOD, which 
translates to a sample size of about 6,100 total CCTA patients (if prevalence of 
hsTnI<LOD is 6%). Therefore a large multi-center study is needed to substantiate 
our study findings. 
Secondly, since we enrolled only patients who received a CCTA at the discretion 
of their treating clinicians, our findings are applicable only to patients to CCTA 
candidates and not to the entire population of suspected ACS patients. 
Therefore, the use of hsTnI as a triage test for determining risk for significant 
coronary artery stenosis should be restricted to patients in whom a CCTA is 





Our study demonstrates that hsTnI is higher in patients with significant coronary 
artery stenosis than in those without. Additionally, our results demonstrate that 
patients with undetectable hsTnI have low likelihood of significant coronary artery 









Table 4.1: Demographic Characteristics of 206 Subjects Studied  
Characteristic Number (%) 
Median Age in years (IQR) 50.9 (45.3 – 57.6) 
Gender  
• Female 114 (55.3) 
• Male 92 (44.7) 
Ethnicity  
• Non-Hispanic Black 139 (67.5) 
• Non-Hispanic White 49 (23.8) 
• Hispanic 7 (3.4) 
• Asian 3 (1.5) 
• Native-American 7 (3.4) 
• Native-Hawaiian 1 (0.5) 
Insurance  
• Medicare 34 (16.5) 
• Medicaid 54 (26.2) 
• Commercial 89 (43.2) 
• HMO 5 (2.4) 
• VA 2 (1.0) 
• None 22 (10.7) 
Transportation  
• Self-transport 172 (83.5) 
• Ambulance 28 (13.6) 
• Transfer from other facility 6 (2.9) 
Current cigarette smoker 90 (43.7) 
Current cocaine use 7 (3.4) 
Family history of AMI or sudden cardiac 
death 
71 (34.5) 
History of hypertension 102 (49.5) 
History of diabetes 44 (21.4) 
History of high cholesterol 64 (31.1) 
History of congestive heart failure 7 (3.4) 











































Figure 4.2: High sensitivity troponin I values in patients according to 
severity of CAD 
 
Table 4.2: 2 X 2 table at 3.2 ng.L cutoff for discriminating significant 
stenosis 
 
 hsTnI>1.2 ng/L hsTnI<=1.2 ng/L  
Stenosis >50%   19   0  19 
Stenosis <50% 149 38 187 
 168 38 206 
 



























Chapter 5: Future Directions 
The duration of emergency department (ED) and hospital evaluation for acute 
coronary syndrome (ACS) remains problematic. In a recent report by the Office 
of the Inspector General on Medicare beneficiaries, chest pain was the most 
common reason for observation and short inpatient stays.143 This finding can be 
explained by the fact that although evaluation for ACS often takes many hours, 
more than 85% of patients are often diagnosed with non-life threatening 
conditions and ultimately discharged.2 My goal is to decrease the duration of ED 
evaluation for ACS by translating novel discoveries in biomarkers from bench to 
bedside. There are a number of barriers to rapidly ruling in or ruling out ACS 
within minutes to a few hours of ED presentation. These include: (1) the poor 
sensitivity of the traditional 12 lead ECG for diagnosing AMI;6,7 (2) the need for 
serial measurements of cardiac troponins; and (3) the lack of biomarkers that can 
detect ischemic myocardial injury with acceptable diagnostic accuracy, resulting 
in the use of time and resource consuming tests such as coronary CT 
angiography, stress tests and cardiac catheterization. The next phases of this 
research will focus on the latter 2 barriers. 
Circumventing the need for prolonged serial troponin measurements 
Troponin measurements are central to the diagnosis of acute myocardial 
infarction (AMI).9 Although clinical use of high sensitivity troponin I (hsTnI) assays 
will result improved diagnosis of AMI at ED presentation, we have demonstrated 




an increase in the prevalence of elevated hsTnI among patients with a primary 
non-cardiac diagnosis. Thus, serial cTnI measurements will be needed to 
distinguish between acute and non-acute causes of elevated troponin. 
Recommendations for the duration of serial troponin measurements vary 
between expert groups. For example, the 2010 International Consensus on 
Cardiopulmonary Resuscitation recommends repeat troponin measurement 
between 6 and 12 hours after symptom onset, for patients who present within 6 
hours of symptom onset.144 The National Academy of Clinical Biochemistry and 
Laboratory Medicine 2007 Practice Guidelines recommend repeat 
measurements 6-9 hours after symptom onset.145  Recommendations from the 
2010 AHA Scientific Statement on testing of low-risk ED chest pain patients are 
for repeat cardiac biomarker measurements 6 to 8 hours after onset of 
symptoms.127 With hsTn, the European Society of Cardiology recommends 
measuring hsTn at presentation and 3 hours after admission.95 However, they 
acknowledge although the data is limited, some patients may still require a 6 
hour sample for definitive diagnosis.53  
In the next phase of this work, I will determine whether serial sampling at 
presentation and 3 hours after presentation is adequate to safely rule out 
AMI using hsTnI. Additionally, I propose an alternate approach to decreasing 
the duration of serial hsTnI sampling, which involves quantification of both 
intact and degraded forms of cTnI, may reflect functional status of the heart 




As mentioned in chapter 1, prior studies have demonstrated that following 
myocardial injury, both cardiac troponin I (cTnI) and cardiac troponin T (cTnT) 
undergo degradation in a time-dependent pattern.33,146 The amount of degraded 
fragments increases with increasing time from onset of injury. A recent study 
analyzed 18 patients with AMI and found intact cTnT present in only 3 patients 
within the first 8 hours after hospital admission. We hypothesize that patients with 
acute and ongoing myocardial infarction may have predominantly intact cTnI 
whereas those with old injuries or chronic troponin elevations may have 
predominantly degraded cTnI. Thus among those with an elevated hsTnI, those 
with predominantly intact cTnI will need acute intervention to treat the underlining 
cause of myocardial injury, whereas those with predominantly degraded cTnI and 
a non-rising hsTnI pattern, may benefit from expedited outpatient evaluation. 
Working with Dr. Pingbo Zhang in the Van Eyk lab, we will test our hypothesis on 
a cohort of ED patients evaluated for ACS, using a novel quantitative mass 
spectrometry assay that is able to quantify total cTnI and the N- and C-terminal 
regions. This allows determination of the extent of proteolysis in each sample 
along with providing a cTnI concentration.   
Furthermore, we will also determine whether a combination of risk factors for 
CAD and hsTnI values allows the identification of a subset of the ED suspected 
ACS population with low risk for adverse cardiac events, who can be rapidly 
discharged. 




Despite numerous attempts, the search for biomarkers of myocardial ischemia 
remains elusive. Prior studies have described associations between a number of 
biomarkers and myocardial ischemia. Ischemia modified albumin (IMA) is one of 
the most studied biomarkers of ischemia.147 IMA levels are high is patients who 
develop chest pain and ST segment changes during PCI.148  There are 
conflicting results regarding whether IMA adds diagnostic value to troponin and 
ECG results.149,150 Although IMA have adequate negative predictive value,149 
there are many instances where elevated values cannot be easily explained, 
leading to a poor positive predictive value. In the coming months, I will be 
working with Dr. Christine Jelinek in Dr. Van Eyk’s lab, to determine whether the 
quantification of post-translational modifications of albumin during myocardial 
ischemia may help improve the specificity of this candidate biomarker for 
myocardial infarction.  Cysteine modifications to the N-terminus of albumin, as 
well as differences in the albumin-binding partners are being measured using the 
quantitative mass spectrometry method mentioned above.  
Additionally a number of candidate biomarkers of ischemia have been discovered 
by work done in the Van Eyk lab. In the coming months to years, we plan to 
conduct clinical validation studies.  
In conclusion, with the use of hsTnI, we AMI will be diagnosed earlier in a subset 
of patients who were previously initial cTnI negative. However, it will also result in 
a significant increase in the number of patients with elevated hsTnI values. 
Although majoriry of patients with new hsTnI elevations will not have AMI, they 




remain hsTnI negative. There remains an unmet clinical need for novel methods 
of distinguishing between AMI and chronic hsTnI elevation. Quantification of cTnI 
disease-induced modified forms, albumin modified forms, or new markers of 
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15. 2/11/2009, Approach to Altered Mental Status (Tricyclic 
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16. 2/21/2009, Sepsis: Infected Kidney Stone 
17. 3/3/2009, Approach to Back Pain 
18. 3/3/2009, Approach to altered mental Status 
19. 3/3/2009, Pediatric fever 
20. 3/3/2009, Pediatric cardiac arrest 
21. 3/3/2009, Pediatric cardiac arrest  
22. 3/3/2009, Transvenous pacer placement 
23. 3/18/2009, Pediatric fever 
24. 3/18/2009, Pediatric arrest 
25. 3/18/2009, Transvenous pacer placement 
26. 3/12/2009, Pediatric fever 
27. 3/12/2009, Pediatric arrest 
28. 3/12/2009, Transvenous pacer placement 





30. 5/5/2009, Sepsis: Infected Kidney Stone 
31. 8/28/2009, Sepsis: Infected Kidney Stone 
32. 8/28/2009, Clinical Diligence: Approach to patient with 
Thrombotic Thrompocytopenic Purpura 
33. 9/9/2009, Sepsis: Infected Kidney Stone 
34. 9/9/2009, Clinical Diligence: Approach to patient with 
Thrombotic Thrompocytopenic Purpura 
35.  9/9/2009, Approach to Altered Mental Status (hepatic 
encephalopathy) 
36. 9/9/2009, Approach to Back Pain 
37. 9/17/2009, Transvenous pacemaker placement 
38. 10/9/2009, Approach to Altered Mental Status (hepatic 
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39. 10/9/2009, Approach to Back Pain 
40. 11/17/2009, Approach to Altered Mental Status (hepatic 
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41. 11/17/2009, 12/7, Sepsis II: Infected Kidney Stone 
42. 12/7/2009, Approach to AMS I (Hepatic encephalopathy) 
43. 12/15/2009, Transvenous pacemaker placement 
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45. 12/22/2009, Approach to AMS I (Hepatic encephalopathy) 
46. 1/20/2010, Approach to AMS I (Hepatic encephalopathy) 
47. 1/20/2010, Clinical diligence: Indentifying patient with TTP 
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• Member, American College of Emergency Physicians, 2003 - 
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• Member, Society for Academic Emergency Medicine, 2003 - 
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• Member, SAEM Simulation Interest Group, 2005 - present 
• Member, Society for Medical Simulation, 2005 – present 
• Member, American Heart Association, 2011 - present 
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• Roundtable sessions chair, 2010 International Meeting on 








• Presidential Merit Scholarship, Morris Brown College, 1996 - 1999 
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• Goldberg Family Charitable Trust Travel Award, Northwestern 
Memorial Foundation, 2006 
• 2009 Doctors Day donation by patient to JHH in my honor 
• Nominee, Attending of the year, Johns Hopkins University School 
of Medicine, Department of Emergency Medicine, 2007 
• Teacher of the Year, Johns Hopkins University School of 
Medicine, Department of Emergency Medicine, 2010 
• KL2 Clinical Research Scholar, Johns Hopkins Institute for Clinical 
and Translational Research, 2010 
• Best presentation, Research Day, Johns Hopkins University School 




• Attending of the Year, Johns Hopkins University School of 
Medicine, Department of Emergency Medicine, 2011 
• Scholar Abstract Award, 2012 Clinical Translational Science Annual 
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